Transcriptional	O
regulation	O
of	O
the	O
interleukin-2	B-DNA
gene	I-DNA
in	O
normal	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Convergence	O
of	O
costimulatory	O
signals	O
and	O
differences	O
from	O
transformed	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

To	O
study	O
transcriptional	O
regulation	O
in	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
we	O
have	O
optimized	O
conditions	O
for	O
transient	O
transfection	O
.	O

Interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
promoter	I-DNA
-reporter	B-DNA
gene	I-DNA
behavior	O
closely	O
parallels	O
the	O
endogenous	B-DNA
gene	I-DNA
in	O
response	O
to	O
T	B-protein
cell	I-protein
receptor	I-protein
and	O
costimulatory	O
signals	O
.	O

As	O
assessed	O
with	O
mutagenized	B-DNA
promoters	I-DNA
,	O
the	O
most	O
important	O
IL-2	B-DNA
cis-regulatory	I-DNA
elements	I-DNA
in	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
are	O
the	O
proximal	B-DNA
AP-1	I-DNA
site	I-DNA
and	O
the	O
NF-	B-DNA
kappaB	I-DNA
site	I-DNA
.	O

Both	O
primary	O
activation	O
,	O
with	O
phytohemagglutinin	B-protein
or	O
antibodies	B-protein
to	I-protein
CD3	I-protein
,	O
and	O
costimulation	O
,	O
provided	O
by	O
pairs	O
of	O
CD2	B-protein
antibodies	I-protein
or	O
B7-positive	B-cell_type
(	I-cell_type
B	I-cell_type
cells	I-cell_type
)	I-cell_type
or	O
B7-negative	B-cell_type
(	I-cell_type
endothelial	I-cell_type
)	I-cell_type
accessory	I-cell_type
cells	I-cell_type
,	I-cell_type
are	O
mediated	O
through	O
the	O
same	O
cis-elements	B-DNA
.	O

Interestingly	O
,	O
the	O
nuclear	B-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cell	I-DNA
sites	I-DNA
are	O
much	O
less	O
important	O
in	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
than	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

We	O
conclude	O
that	O
IL-2	B-protein
transcriptional	O
regulation	O
differs	O
in	O
tumor	B-cell_line
cell	I-cell_line
lines	I-cell_line
compared	O
with	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
that	O
different	O
costimulatory	O
signals	O
converge	O
on	O
the	O
same	O
cis-elements	B-DNA
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

THs	NULL
JourNaL	NULL
or	NULL
BroLocicaL	NULL
CHEMISTRY	NULL
Â©	NULL
1996	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

271	NULL
,	NULL
No	NULL
.	NULL

10	NULL
,	NULL
Issue	NULL
of	NULL
March	NULL
8	NULL
,	NULL
pp	NULL
.	NULL

5369-5377	NULL
,	NULL
1996	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Transcriptional	NULL
Regulation	NULL
of	NULL
the	NULL
Interleukin-2	NULL
Gene	NULL
in	NULL
Normal	NULL
Human	NULL
Peripheral	NULL
Blood	NULL
T	NULL
Cells	NULL
CONVERGENCE	NULL
OF	NULL
COSTIMULATORY	NULL
SIGNALS	NULL
AND	NULL
DIFFERENCES	NULL
FROM	NULL
TRANSFORMED	NULL
T	NULL
CELLS*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
September	NULL
27	NULL
,	NULL
1995	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
December	NULL
20	NULL
,	NULL
1995	NULL
)	NULL
Christopher	NULL
C.	NULL
W.	NULL
Hughes	NULL
$	NULL
#	NULL
and	NULL
Jordan	NULL
S.	NULL
Pober	NULL
From	NULL
the	NULL
Molecular	NULL
Cardiobiology	NULL
Program	NULL
,	NULL
Boyer	NULL
Center	NULL
for	NULL
Molecular	NULL
Medicine	NULL
,	NULL
Yale	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
New	NULL
Haven	NULL
,	NULL
Connecticut	NULL
06536	NULL
To	NULL
study	NULL
transcriptional	NULL
regulation	NULL
in	NULL
normal	NULL
human	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
have	NULL
optimized	NULL
conditions	NULL
for	NULL
transient	NULL
transfection	NULL
.	NULL

Interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
promoter-reporter	NULL
gene	NULL
behavior	NULL
closely	NULL
parallels	NULL
the	NULL
endogenous	NULL
gene	NULL
in	NULL
response	NULL
to	NULL
T	NULL
cell	NULL
receptor	NULL
and	NULL
costimulatory	NULL
signals	NULL
.	NULL

As	NULL
assessed	NULL
with	NULL
mutagenized	NULL
promoters	NULL
,	NULL
the	NULL
most	NULL
important	NULL
IL-2	NULL
cis-regulatory	NULL
elements	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
are	NULL
the	NULL
proximal	NULL
AP-1	NULL
site	NULL
and	NULL
the	NULL
NF-KB	NULL
site	NULL
.	NULL

Both	NULL
primary	NULL
activation	NULL
,	NULL
with	NULL
phytohemagglutinin	NULL
or	NULL
antibodies	NULL
to	NULL
CD3	NULL
,	NULL
and	NULL
costimulation	NULL
,	NULL
provided	NULL
by	NULL
pairs	NULL
of	NULL
CD2	NULL
antibodies	NULL
or	NULL
B7-positive	NULL
(	NULL
B	NULL
cells	NULL
)	NULL
or	NULL
B7-negative	NULL
(	NULL
endothe-lial	NULL
)	NULL
accessory	NULL
cells	NULL
,	NULL
are	NULL
mediated	NULL
through	NULL
the	NULL
same	NULL
cis-elements	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cell	NULL
sites	NULL
are	NULL
much	NULL
less	NULL
important	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
than	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
IL-2	NULL
transcriptional	NULL
regulation	NULL
differs	NULL
in	NULL
tumor	NULL
cell	NULL
lines	NULL
compared	NULL
with	NULL
normal	NULL
T	NULL
cells	NULL
and	NULL
that	NULL
different	NULL
costimulatory	NULL
signals	NULL
converge	NULL
on	NULL
the	NULL
same	NULL
cis-elements	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

The	NULL
initiation	NULL
of	NULL
an	NULL
immune	NULL
response	NULL
involves	NULL
interaction	NULL
between	NULL
foreign	NULL
antigenic	NULL
peptide	NULL
bound	NULL
to	NULL
major	NULL
histocompatibility	NULL
complex	NULL
(	NULL
MHC	NULL
)	NULL
molecules	NULL
on	NULL
the	NULL
antigen-presenting	NULL
cell	NULL
(	NULL
APC	NULL
)	NULL
and	NULL
a	NULL
cognate	NULL
antigen	NULL
receptor	NULL
on	NULL
the	NULL
T	NULL
cell	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Under	NULL
physiological	NULL
conditions	NULL
,	NULL
specific	NULL
antigen-MHC	NULL
complexes	NULL
are	NULL
usually	NULL
limiting	NULL
,	NULL
and	NULL
T	NULL
cells	NULL
require	NULL
additional	NULL
costimulatory	NULL
signals	NULL
to	NULL
be	NULL
fully	NULL
activated	NULL
(	NULL
2	NULL
)	NULL
.	NULL

The	NULL
major	NULL
source	NULL
of	NULL
such	NULL
signals	NULL
appears	NULL
to	NULL
be	NULL
direct	NULL
interaction	NULL
of	NULL
cell	NULL
surface	NULL
ligands	NULL
on	NULL
the	NULL
T	NULL
cell	NULL
and	NULL
the	NULL
APC	NULL
.	NULL

T	NULL
cells	NULL
that	NULL
receive	NULL
the	NULL
correct	NULL
combination	NULL
of	NULL
T	NULL
cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
-mediated	NULL
and	NULL
costimulatory	NULL
signals	NULL
enter	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
express	NULL
activation	NULL
antigens	NULL
such	NULL
as	NULL
CD69	NULL
and	NULL
CD25	NULL
,	NULL
and	NULL
begin	NULL
synthesis	NULL
of	NULL
several	NULL
cytokines	NULL
,	NULL
including	NULL
the	NULL
T	NULL
cell	NULL
autocrine/	NULL
paracrine	NULL
growth	NULL
factor	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
.	NULL

IL-2	NULL
is	NULL
an	NULL
essential	NULL
factor	NULL
required	NULL
for	NULL
progression	NULL
of	NULL
newly	NULL
activated	NULL
T	NULL
cells	NULL
from	NULL
G	NULL
,	NULL
to	NULL
S	NULL
phase	NULL
,	NULL
and	NULL
the	NULL
quantity	NULL
of	NULL
IL-2	NULL
produced	NULL
is	NULL
a	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
HL51014	NULL
and	NULL
HL	NULL
48364	NULL
.	NULL

The	NULL
Molecular	NULL
Cardiobiology	NULL
Program	NULL
at	NULL
the	NULL
Boyer	NULL
Center	NULL
for	NULL
Molecular	NULL
Medicine	NULL
is	NULL
supported	NULL
by	NULL
Lederle	NULL
Labora-tories	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1784	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
}	NULL

To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
Dept	NULL
.	NULL

of	NULL
Molecular	NULL
Biology	NULL
and	NULL
Biochemistry	NULL
,	NULL
Bio	NULL
Sci	NULL
II	NULL
,	NULL
University	NULL
of	NULL
California	NULL
at	NULL
Irvine	NULL
,	NULL
Irvine	NULL
,	NULL
CA	NULL
92717	NULL
.	NULL

*The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
MHC	NULL
,	NULL
major	NULL
histocompatibility	NULL
com-plex	NULL
;	NULL
APC	NULL
,	NULL
antigen-presenting	NULL
cell	NULL
(	NULL
s	NULL
)	NULL
;	NULL
TCR	NULL
,	NULL
T	NULL
cell	NULL
receptor	NULL
;	NULL
IL	NULL
,	NULL
interleu-kin	NULL
;	NULL
NFAT	NULL
,	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
;	NULL
dNFAT	NULL
,	NULL
distal	NULL
NFAT	NULL
;	NULL
pNFAT	NULL
,	NULL
proximal	NULL
NFAT	NULL
;	NULL
EC	NULL
,	NULL
endothelial	NULL
cell	NULL
(	NULL
s	NULL
)	NULL
;	NULL
pAP-1	NULL
,	NULL
proximal	NULL
AP-1	NULL
;	NULL
CD28RE	NULL
,	NULL
CD28	NULL
response	NULL
element	NULL
;	NULL
PHA	NULL
,	NULL
phytohemagglutinin	NULL
;	NULL
PBMC	NULL
,	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cell	NULL
(	NULL
s	NULL
)	NULL
;	NULL
FACS	NULL
,	NULL
fluorescence-activated	NULL
cell	NULL
sorting	NULL
;	NULL
mAb	NULL
,	NULL
monoclonal	NULL
antibody	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
;	NULL
PCR	NULL
,	NULL
polymerase	NULL
chain	NULL
reaction	NULL
;	NULL
pOCT	NULL
,	NULL
proximal	NULL
octamer	NULL
.	NULL

major	NULL
determinant	NULL
of	NULL
whether	NULL
an	NULL
effective	NULL
response	NULL
can	NULL
be	NULL
generated	NULL
.	NULL

Moreover	NULL
,	NULL
inadequate	NULL
IL-2	NULL
synthesis	NULL
can	NULL
lead	NULL
to	NULL
T	NULL
cell	NULL
death	NULL
or	NULL
induction	NULL
of	NULL
a	NULL
state	NULL
of	NULL
unresponsiveness	NULL
known	NULL
as	NULL
clonal	NULL
anergy	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Numerous	NULL
T	NULL
cell	NULL
surface	NULL
molecules	NULL
have	NULL
been	NULL
suggested	NULL
as	NULL
mediators	NULL
of	NULL
costimulatory	NULL
signals	NULL
,	NULL
the	NULL
best	NULL
characterized	NULL
being	NULL
CD2	NULL
,	NULL
interacting	NULL
primarily	NULL
with	NULL
CD58	NULL
(	NULL
LFA-3	NULL
)	NULL
and	NULL
CD59	NULL
on	NULL
the	NULL
APC	NULL
(	NULL
5-8	NULL
)	NULL
,	NULL
and	NULL
CD28	NULL
,	NULL
interacting	NULL
with	NULL
CD80	NULL
(	NULL
B7-1	NULL
)	NULL
and	NULL
CD86	NULL
(	NULL
B7-2/B70	NULL
)	NULL
on	NULL
the	NULL
APC	NULL
(	NULL
9-13	NULL
)	NULL
.	NULL

CTLA-4	NULL
is	NULL
a	NULL
second	NULL
T	NULL
cell	NULL
molecule	NULL
that	NULL
interacts	NULL
with	NULL
the	NULL
same	NULL
ligands	NULL
as	NULL
CD28	NULL
and	NULL
may	NULL
also	NULL
mediate	NULL
costimulatory	NULL
signals	NULL
(	NULL
14	NULL
)	NULL
,	NULL
although	NULL
this	NULL
has	NULL
been	NULL
disputed	NULL
(	NULL
15	NULL
,	NULL
16	NULL
)	NULL
.	NULL

However	NULL
,	NULL
costimulatory	NULL
activity	NULL
is	NULL
not	NULL
limited	NULL
to	NULL
these	NULL
molecules	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
.	NULL

Both	NULL
the	NULL
CD2	NULL
and	NULL
CD28	NULL
pathways	NULL
of	NULL
costimulation	NULL
are	NULL
thought	NULL
to	NULL
increase	NULL
the	NULL
level	NULL
of	NULL
IL-2	NULL
transcription	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
,	NULL
although	NULL
this	NULL
may	NULL
not	NULL
be	NULL
the	NULL
case	NULL
for	NULL
CD28	NULL
in	NULL
murine	NULL
T	NULL
cell	NULL
clones	NULL
(	NULL
19	NULL
)	NULL
.	NULL

CD28-mediated	NULL
signals	NULL
may	NULL
additionally	NULL
stabilize	NULL
IL-2	NULL
mRNA	NULL
and	NULL
affect	NULL
post-transcriptional	NULL
nuclear	NULL
processing	NULL
(	NULL
19	NULL
,	NULL
20	NULL
)	NULL
.	NULL

The	NULL
IL-2	NULL
gene	NULL
is	NULL
not	NULL
actively	NULL
transcribed	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
.	NULL

Transcription	NULL
of	NULL
IL-2	NULL
can	NULL
be	NULL
detected	NULL
as	NULL
early	NULL
as	NULL
40	NULL
min	NULL
after	NULL
activation	NULL
,	NULL
leading	NULL
to	NULL
peak	NULL
levels	NULL
of	NULL
mRNA	NULL
around	NULL
6	NULL
h	NULL
and	NULL
a	NULL
return	NULL
to	NULL
near	NULL
zero	NULL
levels	NULL
by	NULL
12-18	NULL
h	NULL
(	NULL
2	NULL
,	NULL
5	NULL
)	NULL
.	NULL

Approximately	NULL
300	NULL
base	NULL
pairs	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
are	NULL
sufficient	NULL
to	NULL
confer	NULL
cell-specific	NULL
,	NULL
inducible	NULL
expression	NULL
to	NULL
reporter	NULL
gene	NULL
constructs	NULL
(	NULL
21	NULL
)	NULL
,	NULL
although	NULL
other	NULL
regulatory	NULL
sequences	NULL
may	NULL
lie	NULL
outside	NULL
of	NULL
this	NULL
region	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Within	NULL
these	NULL
300	NULL
base	NULL
pairs	NULL
,	NULL
several	NULL
transcription	NULL
factor-binding	NULL
sites	NULL
have	NULL
been	NULL
identified	NULL
as	NULL
positive	NULL
regulatory	NULL
elements	NULL
in	NULL
tumor	NULL
T	NULL
cells	NULL
(	NULL
see	NULL
Table	NULL
II	NULL
)	NULL
,	NULL
including	NULL
proximal	NULL
and	NULL
distal	NULL
specific	NULL
sequences	NULL
for	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NFAT	NULL
)	NULL
(	NULL
21	NULL
,	NULL
23	NULL
,	NULL
24	NULL
)	NULL
and	NULL
proximal	NULL
and	NULL
distal	NULL
sequences	NULL
for	NULL
AP-1	NULL
(	NULL
25	NULL
,	NULL
26	NULL
)	NULL
,	NULL
for	NULL
NF-	NULL
Â«	NULL
B	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
,	NULL
for	NULL
NIL-2A	NULL
(	NULL
29	NULL
)	NULL
,	NULL
for	NULL
CD28-activated	NULL
factors	NULL
(	NULL
30	NULL
)	NULL
,	NULL
and	NULL
for	NULL
octamer	NULL
factors	NULL
(	NULL
31	NULL
)	NULL
.	NULL

An	NULL
additional	NULL
AP-1	NULL
site	NULL
has	NULL
also	NULL
recently	NULL
been	NULL
identified	NULL
just	NULL
downstream	NULL
of	NULL
the	NULL
dNFAT	NULL
sequence	NULL
(	NULL
25	NULL
)	NULL
,	NULL
which	NULL
we	NULL
have	NULL
designated	NULL
as	NULL
NFAP-1	NULL
as	NULL
it	NULL
appears	NULL
to	NULL
be	NULL
functionally	NULL
a	NULL
part	NULL
of	NULL
the	NULL
``	NULL
NFAT	NULL
``	NULL
binding	NULL
sequence	NULL
.	NULL

Also	NULL
,	NULL
a	NULL
binding	NULL
site	NULL
for	NULL
SP1	NULL
and	NULL
EGR-1	NULL
has	NULL
been	NULL
identified	NULL
immediately	NULL
upstream	NULL
of	NULL
the	NULL
distal	NULL
NFAT	NULL
site	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Many	NULL
of	NULL
these	NULL
sites	NULL
vary	NULL
from	NULL
consensus	NULL
sequences	NULL
in	NULL
other	NULL
genes	NULL
,	NULL
and	NULL
it	NULL
appears	NULL
that	NULL
these	NULL
differences	NULL
account	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
for	NULL
the	NULL
T	NULL
cell-specific	NULL
expression	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
(	NULL
33	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
T	NULL
cells	NULL
through	NULL
the	NULL
TCR-CD3	NULL
signaling	NULL
pathway	NULL
leads	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
transcription	NULL
factors	NULL
specific	NULL
to	NULL
several	NULL
of	NULL
these	NULL
sites	NULL
.	NULL

It	NULL
has	NULL
been	NULL
proposed	NULL
that	NULL
costimulatory	NULL
signals	NULL
increase	NULL
transcription	NULL
by	NULL
either	NULL
1	NULL
)	NULL
altering	NULL
the	NULL
composition	NULL
of	NULL
transcription	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
sites	NULL
targeted	NULL
by	NULL
TCR/CD3-derived	NULL
signals	NULL
or	NULL
2	NULL
)	NULL
inducing	NULL
new	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
novel	NULL
combinations	NULL
of	NULL
sites	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
presented	NULL
evidence	NULL
that	NULL
human	NULL
umbilical	NULL
vein	NULL
endothelial	NULL
cell	NULL
(	NULL
EC	NULL
)	NULL
costimulation	NULL
modifies	NULL
the	NULL
composition	NULL
of	NULL
the	NULL
AP-1	NULL
complex	NULL
binding	NULL
to	NULL
the	NULL
proximal	NULL
AP-1	NULL
(	NULL
pAP-1	NULL
)	NULL
site	NULL
in	NULL
mitogen-activated	NULL
T	NULL
5369	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10Â°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
5370	NULL
IL-2	NULL
Transcription	NULL
in	NULL
Peripheral	NULL
Blood	NULL
Lymphocytes	NULL
cells	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
in	NULL
murine	NULL
LBRM-33	NULL
cells	NULL
,	NULL
IL-1	NULL
induces	NULL
c-Jun	NULL
,	NULL
which	NULL
combines	NULL
with	NULL
c-Fos	NULL
protein	NULL
induced	NULL
by	NULL
TCR-mediated	NULL
signals	NULL
,	NULL
and	NULL
binds	NULL
to	NULL
the	NULL
AP-1	NULL
sites	NULL
(	NULL
85	NULL
)	NULL
.	NULL

IL-1	NULL
also	NULL
induces	NULL
AP-1	NULL
proteins	NULL
in	NULL
mouse	NULL
EL-4	NULL
cells	NULL
(	NULL
36	NULL
)	NULL
.	NULL

However	NULL
,	NULL
normal	NULL
human	NULL
T	NULL
cells	NULL
constitutively	NULL
express	NULL
high	NULL
levels	NULL
of	NULL
c-Jun	NULL
and	NULL
do	NULL
not	NULL
respond	NULL
to	NULL
IL-1	NULL
as	NULL
a	NULL
costimulator	NULL
(	NULL
34	NULL
)	NULL
.	NULL

In	NULL
Jurkat	NULL
cells	NULL
,	NULL
CD28	NULL
has	NULL
been	NULL
found	NULL
to	NULL
induce	NULL
a	NULL
transcription	NULL
factor	NULL
composed	NULL
of	NULL
NFKB1	NULL
(	NULL
p50	NULL
)	NULL
,	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
,	NULL
and	NULL
c-Rel	NULL
(	NULL
37	NULL
,	NULL
38	NULL
)	NULL
that	NULL
binds	NULL
to	NULL
a	NULL
variant	NULL
NF-	NULL
Â«	NULL
B	NULL
site	NULL
called	NULL
the	NULL
CD28	NULL
response	NULL
element	NULL
(	NULL
CD28RE	NULL
)	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
this	NULL
site	NULL
has	NULL
been	NULL
found	NULL
to	NULL
be	NULL
also	NULL
targeted	NULL
by	NULL
signals	NULL
other	NULL
than	NULL
CD28	NULL
(	NULL
40	NULL
)	NULL
.	NULL

It	NULL
is	NULL
not	NULL
known	NULL
whether	NULL
different	NULL
accessory	NULL
cell	NULL
types	NULL
activate	NULL
different	NULL
combinations	NULL
of	NULL
nuclear	NULL
factors	NULL
.	NULL

Much	NULL
of	NULL
the	NULL
information	NULL
on	NULL
IL-2	NULL
transcription	NULL
has	NULL
been	NULL
obtained	NULL
from	NULL
studies	NULL
of	NULL
tumor	NULL
cell	NULL
lines	NULL
such	NULL
as	NULL
Jurkat	NULL
,	NULL
LBRM-33	NULL
,	NULL
and	NULL
EL-4	NULL
,	NULL
although	NULL
recently	NULL
,	NULL
the	NULL
role	NULL
of	NULL
NF-	NULL
Â«	NULL
B	NULL
regulation	NULL
in	NULL
IL-2	NULL
transcription	NULL
has	NULL
been	NULL
studied	NULL
in	NULL
CD4*	NULL
T	NULL
cell	NULL
clones	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Little	NULL
information	NULL
is	NULL
available	NULL
on	NULL
transcriptional	NULL
control	NULL
in	NULL
freshly	NULL
isolated	NULL
normal	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
major	NULL
barrier	NULL
to	NULL
such	NULL
studies	NULL
has	NULL
been	NULL
technical	NULL
;	NULL
it	NULL
is	NULL
very	NULL
difficult	NULL
to	NULL
measure	NULL
the	NULL
low	NULL
transcriptional	NULL
rate	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
observed	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
by	NULL
conventional	NULL
assays	NULL
,	NULL
such	NULL
as	NULL
nuclear	NULL
run-off	NULL
.	NULL

Also	NULL
,	NULL
such	NULL
cells	NULL
are	NULL
generally	NULL
resistant	NULL
to	NULL
transfection	NULL
by	NULL
reporter	NULL
genes	NULL
.	NULL

It	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
can	NULL
be	NULL
made	NULL
transfection-competent	NULL
by	NULL
a	NULL
brief	NULL
period	NULL
of	NULL
suboptimal	NULL
stimulation	NULL
with	NULL
the	NULL
polyclonal	NULL
mitogenic	NULL
lectin	NULL
phytohemagglutinin	NULL
(	NULL
PHA	NULL
)	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Unfortunately	NULL
,	NULL
this	NULL
approach	NULL
has	NULL
proven	NULL
inconsistent	NULL
and	NULL
has	NULL
not	NULL
been	NULL
widely	NULL
used	NULL
.	NULL

Here	NULL
we	NULL
describe	NULL
an	NULL
optimization	NULL
of	NULL
this	NULL
technique	NULL
that	NULL
permits	NULL
routine	NULL
measurement	NULL
of	NULL
IL-2	NULL
transcription	NULL
,	NULL
which	NULL
is	NULL
responsive	NULL
to	NULL
TCR	NULL
and	NULL
costimulatory	NULL
signals	NULL
,	NULL
in	NULL
small	NULL
numbers	NULL
of	NULL
normal	NULL
human	NULL
blood	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
have	NULL
used	NULL
this	NULL
model	NULL
to	NULL
characterize	NULL
IL-2	NULL
transcription	NULL
in	NULL
normal	NULL
human	NULL
T	NULL
cells	NULL
and	NULL
find	NULL
that	NULL
the	NULL
nuclear	NULL
factor-binding	NULL
sites	NULL
that	NULL
are	NULL
important	NULL
in	NULL
these	NULL
cells	NULL
differ	NULL
from	NULL
those	NULL
required	NULL
for	NULL
optimal	NULL
transcription	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
have	NULL
characterized	NULL
the	NULL
sites	NULL
required	NULL
for	NULL
responsiveness	NULL
to	NULL
various	NULL
costimulatory	NULL
signals	NULL
and	NULL
accessory	NULL
cell	NULL
types	NULL
.	NULL

EXPERIMENTAL	NULL
PROCEDURES	NULL
Preparation	NULL
and	NULL
Transfection	NULL
of	NULL
T	NULL
Cells-Normal	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMC	NULL
)	NULL
were	NULL
prepared	NULL
by	NULL
centrifugation	NULL
of	NULL
whole	NULL
blood	NULL
over	NULL
lymphocyte	NULL
separation	NULL
medium	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
(	NULL
Litton	NULL
Bionetics	NULL
,	NULL
Kensington	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

Blood	NULL
was	NULL
obtained	NULL
by	NULL
venipuncture	NULL
of	NULL
normal	NULL
healthy	NULL
donors	NULL
.	NULL

Cells	NULL
were	NULL
cultured	NULL
for	NULL
19.5-20	NULL
h	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
antibiotics	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
,	NULL
and	NULL
50	NULL
mM	NULL
2-mercaptoethanol	NULL
with	NULL
1	NULL
ug/ml	NULL
PHA-L	NULL
(	NULL
Sigma	NULL
)	NULL
at	NULL
3	NULL
X	NULL
10Â°	NULL
cells/ml	NULL
to	NULL
induce	NULL
transfection	NULL
competence	NULL
.	NULL

After	NULL
washing	NULL
,	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
fresh	NULL
lymphocyte	NULL
medium	NULL
at	NULL
2	NULL
X	NULL
10Â¢/ml	NULL
.	NULL

Aliquots	NULL
of	NULL
0.25	NULL
ml	NULL
were	NULL
electroporated	NULL
in	NULL
a	NULL
Bio-Rad	NULL
Gene	NULL
Pulser	NULL
at	NULL
250	NULL
V	NULL
and	NULL
960	NULL
microfarads	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
60	NULL
ug/ml	NULL
reporter	NULL
gene	NULL
DNA	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

Where	NULL
different	NULL
mutant	NULL
promoters	NULL
were	NULL
being	NULL
compared	NULL
in	NULL
a	NULL
single	NULL
experiment	NULL
,	NULL
pXGH	NULL
(	NULL
growth	NULL
hormone	NULL
driven	NULL
by	NULL
the	NULL
metallothionein	NULL
promoter	NULL
)	NULL
or	NULL
pCMV-B-gal	NULL
(	NULL
B-galactosidase	NULL
driven	NULL
by	NULL
the	NULL
cytomegalovirus	NULL
promoter	NULL
)	NULL
(	NULL
10	NULL
pg/ml	NULL
)	NULL
was	NULL
added	NULL
to	NULL
control	NULL
for	NULL
transfection	NULL
efficiency	NULL
.	NULL

Normalizing	NULL
for	NULL
transfection	NULL
efficiency	NULL
was	NULL
not	NULL
necessary	NULL
when	NULL
a	NULL
single	NULL
promoter	NULL
(	NULL
usually	NULL
wild-type	NULL
)	NULL
was	NULL
being	NULL
assayed	NULL
under	NULL
different	NULL
condi-tions	NULL
;	NULL
here	NULL
separate	NULL
transfections	NULL
were	NULL
pooled	NULL
before	NULL
use	NULL
.	NULL

The	NULL
gap	NULL
width	NULL
of	NULL
the	NULL
cuvettes	NULL
was	NULL
0.4	NULL
em	NULL
,	NULL
which	NULL
resulted	NULL
in	NULL
a	NULL
7	NULL
of	NULL
45-50	NULL
ms.	NULL
Jurkat	NULL
cells	NULL
,	NULL
treated	NULL
with	NULL
PHA	NULL
in	NULL
parallel	NULL
with	NULL
PBMC	NULL
,	NULL
were	NULL
electroporated	NULL
under	NULL
the	NULL
same	NULL
conditions	NULL
,	NULL
except	NULL
that	NULL
a	NULL
volume	NULL
of	NULL
0.5	NULL
ml	NULL
was	NULL
used	NULL
,	NULL
which	NULL
reduced	NULL
r	NULL
to	NULL
20-25	NULL
ms.	NULL
After	NULL
electroporation	NULL
,	NULL
cells	NULL
were	NULL
immediately	NULL
removed	NULL
and	NULL
added	NULL
to	NULL
10	NULL
ml	NULL
of	NULL
medium	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
fresh	NULL
medium	NULL
.	NULL

Cells	NULL
were	NULL
plated	NULL
(	NULL
see	NULL
below	NULL
)	NULL
after	NULL
resting	NULL
for	NULL
2	NULL
h	NULL
at	NULL
37	NULL
Â°C	NULL
.	NULL

Sorting	NULL
of	NULL
Cells	NULL
by	NULL
FACS-PBMC	NULL
were	NULL
electroporated	NULL
as	NULL
described	NULL
above	NULL
and	NULL
then	NULL
incubated	NULL
with	NULL
antibodies	NULL
directly	NULL
conjugated	NULL
with	NULL
fluorescein	NULL
isothiocyanate	NULL
or	NULL
phycoerythrin	NULL
for	NULL
20	NULL
min	NULL
on	NULL
ice	NULL
in	NULL
phos-phate-buffered	NULL
saline	NULL
,	NULL
0.1	NULL
%	NULL
mouse	NULL
serum	NULL
.	NULL

After	NULL
washing	NULL
,	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
,	NULL
0.5	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
and	NULL
aliquots	NULL
were	NULL
sorted	NULL
on	NULL
a	NULL
FACScan	NULL
cell	NULL
sorter	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

mAbs	NULL
used	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
anti-CD4-fluorescein	NULL
isothiocyanate	NULL
and	NULL
anti-CD8-phycoerythrin	NULL
against	NULL
T	NULL
cells	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
anti-CD19-phycoerythrin	NULL
against	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
anti-CD14-fluorescein	NULL
isothiocyanate	NULL
against	NULL
monocytes	NULL
(	NULL
the	NULL
latter	NULL
two	NULL
from	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

Detection	NULL
of	NULL
Reporter	NULL
Genes-For	NULL
detection	NULL
of	NULL
luciferase	NULL
and	NULL
B-galactosidase	NULL
activity	NULL
,	NULL
plates	NULL
were	NULL
spun	NULL
down	NULL
,	NULL
and	NULL
150	NULL
ul	NULL
of	NULL
medium	NULL
was	NULL
removed	NULL
(	NULL
this	NULL
was	NULL
saved	NULL
for	NULL
IL-2	NULL
bioassay	NULL
;	NULL
see	NULL
below	NULL
)	NULL
.	NULL

To	NULL
the	NULL
remaining	NULL
50	NULL
pl	NULL
containing	NULL
the	NULL
cells	NULL
was	NULL
added	NULL
100	NULL
pl	NULL
of	NULL
1.5	NULL
X	NULL
reporter	NULL
lysis	NULL
buffer	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
.	NULL

This	NULL
amount	NULL
of	NULL
medium	NULL
did	NULL
not	NULL
interfere	NULL
significantly	NULL
with	NULL
the	NULL
subsequent	NULL
assays	NULL
.	NULL

Light	NULL
output	NULL
from	NULL
luciferase	NULL
was	NULL
assayed	NULL
in	NULL
a	NULL
luminometer	NULL
(	NULL
Berthold	NULL
LB9501	NULL
,	NULL
Wallac	NULL
,	NULL
Gaithers-burg	NULL
,	NULL
MD	NULL
)	NULL
using	NULL
acetyl-CoA	NULL
to	NULL
prolong	NULL
the	NULL
usable	NULL
signal	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

Forty	NULL
ul	NULL
of	NULL
lysate	NULL
was	NULL
assayed	NULL
in	NULL
100	NULL
pl	NULL
of	NULL
assay	NULL
buffer	NULL
.	NULL

Experiments	NULL
were	NULL
performed	NULL
in	NULL
triplicate	NULL
,	NULL
and	NULL
results	NULL
are	NULL
expressed	NULL
as	NULL
mean	NULL
+	NULL
S.E	NULL
.	NULL

Human	NULL
growth	NULL
hormone	NULL
secreted	NULL
into	NULL
the	NULL
medium	NULL
was	NULL
detected	NULL
by	NULL
immunoradioisotopic	NULL
assay	NULL
(	NULL
Nichols	NULL
Institute	NULL
,	NULL
San	NULL
Juan	NULL
Capistrano	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

B-Galactosidase	NULL
activity	NULL
was	NULL
measured	NULL
using	NULL
a	NULL
commercially	NULL
available	NULL
kit	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

Culture	NULL
of	NULL
Endothelial	NULL
Cells	NULL
and	NULL
B	NULL
Cells	NULL
with	NULL
T	NULL
Lymphocytee-Human	NULL
umbilical	NULL
vein	NULL
EC	NULL
were	NULL
plated	NULL
in	NULL
fibronectin-coated	NULL
round	NULL
bottom	NULL
96-well	NULL
plates	NULL
and	NULL
grown	NULL
to	NULL
confluence	NULL
in	NULL
medium	NULL
M199	NULL
containing	NULL
20	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
,	NULL
antibiotics	NULL
,	NULL
endothelial	NULL
cell	NULL
growth	NULL
supplement	NULL
,	NULL
and	NULL
heparin	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
43	NULL
,	NULL
44	NULL
)	NULL
.	NULL

B	NULL
cells	NULL
(	NULL
1	NULL
x	NULL
10*/well	NULL
)	NULL
were	NULL
suspended	NULL
in	NULL
lymphocyte	NULL
medium	NULL
and	NULL
plated	NULL
into	NULL
round	NULL
bottom	NULL
96-well	NULL
plates	NULL
.	NULL

After	NULL
transfection	NULL
and	NULL
washing	NULL
,	NULL
T	NULL
cells	NULL
(	NULL
3	NULL
x	NULL
10Â°/well	NULL
)	NULL
were	NULL
added	NULL
to	NULL
EC	NULL
,	NULL
to	NULL
B	NULL
cells	NULL
,	NULL
or	NULL
alone	NULL
to	NULL
fibronectin-coated	NULL
wells	NULL
in	NULL
lymphocyte	NULL
medium	NULL
.	NULL

This	NULL
number	NULL
of	NULL
T	NULL
cells	NULL
represents	NULL
a	NULL
ratio	NULL
of	NULL
~30:1	NULL
over	NULL
APC	NULL
.	NULL

The	NULL
same	NULL
number	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
was	NULL
added	NULL
to	NULL
similarly	NULL
coated	NULL
wells	NULL
.	NULL

PHA	NULL
was	NULL
used	NULL
at	NULL
5	NULL
ug/ml	NULL
.	NULL

Anti-CD3	NULL
mAb	NULL
OKT3	NULL
was	NULL
bound	NULL
to	NULL
anti-mouse	NULL
Ig-coated	NULL
beads	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
(	NULL
Dynal	NULL
,	NULL
Inc.	NULL
,	NULL
Great	NULL
Neck	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

The	NULL
final	NULL
concentration	NULL
of	NULL
bead-bound	NULL
mAb	NULL
in	NULL
the	NULL
well	NULL
was	NULL
~0.5-1	NULL
ug/ml	NULL
.	NULL

Phorbol	NULL
ester	NULL
(	NULL
PMA	NULL
;	NULL
Sigma	NULL
)	NULL
was	NULL
used	NULL
at	NULL
10	NULL
ng/ml	NULL
and	NULL
ionomycin	NULL
at	NULL
200	NULL
ng/ml	NULL
.	NULL

The	NULL
stimulating	NULL
anti-CD2	NULL
mAbs	NULL
CB6	NULL
and	NULL
GD10	NULL
(	NULL
a	NULL
gift	NULL
of	NULL
Chris	NULL
Benjamin	NULL
,	NULL
Biogen	NULL
Inc.	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
were	NULL
purified	NULL
from	NULL
ascites	NULL
and	NULL
used	NULL
at	NULL
1	NULL
ug/ml	NULL
.	NULL

Anti-CD2	NULL
mAb	NULL
TS2/18	NULL
and	NULL
anti-LFA-3	NULL
mAb	NULL
TS2/9	NULL
(	NULL
a	NULL
gift	NULL
of	NULL
Tim	NULL
Springer	NULL
,	NULL
Center	NULL
for	NULL
Blood	NULL
Research	NULL
,	NULL
Boston	NULL
)	NULL
were	NULL
purified	NULL
from	NULL
ascites	NULL
and	NULL
used	NULL
at	NULL
10	NULL
pg/ml	NULL
.	NULL

Anti-CD28	NULL
mAbs	NULL
3D10	NULL
(	NULL
a	NULL
gift	NULL
of	NULL
Gary	NULL
Gray	NULL
,	NULL
Repligen	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
,	NULL
9.3	NULL
(	NULL
a	NULL
gift	NULL
of	NULL
J.	NULL
Ledbetter	NULL
,	NULL
Bristol-Myers	NULL
Squibb	NULL
,	NULL
Seattle	NULL
)	NULL
,	NULL
and	NULL
L293	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
were	NULL
used	NULL
at	NULL
1	NULL
ug/ml	NULL
.	NULL

CTLA-4-Ig	NULL
fusion	NULL
protein	NULL
,	NULL
control	NULL
Ig	NULL
fusion	NULL
protein	NULL
,	NULL
mAb	NULL
9.3	NULL
Fab	NULL
frag-ments	NULL
,	NULL
and	NULL
control	NULL
Fab	NULL
fragments	NULL
were	NULL
also	NULL
gifts	NULL
of	NULL
Gary	NULL
Gray	NULL
and	NULL
were	NULL
used	NULL
at	NULL
10	NULL
pg/ml	NULL
.	NULL

IL-2	NULL
Bioassay-The	NULL
concentration	NULL
of	NULL
IL-2	NULL
in	NULL
the	NULL
medium	NULL
was	NULL
determined	NULL
by	NULL
HT-2	NULL
bioassay	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
84	NULL
)	NULL
.	NULL

HT-2	NULL
cells	NULL
were	NULL
a	NULL
gift	NULL
of	NULL
A.	NULL
Abbas	NULL
(	NULL
Brigham	NULL
and	NULL
Women	NULL
's	NULL
Hospital	NULL
,	NULL
Boston	NULL
)	NULL
.	NULL

At	NULL
least	NULL
three	NULL
serial	NULL
dilutions	NULL
of	NULL
each	NULL
supernatant	NULL
were	NULL
tested	NULL
,	NULL
and	NULL
results	NULL
are	NULL
shown	NULL
as	NULL
mean	NULL
+	NULL
S.D	NULL
.	NULL

None	NULL
of	NULL
the	NULL
reagents	NULL
used	NULL
were	NULL
found	NULL
to	NULL
significantly	NULL
alter	NULL
HT-2	NULL
cell	NULL
survival	NULL
.	NULL

Generation	NULL
of	NULL
IL-2	NULL
Promoter	NULL
Mutations-A	NULL
600-base	NULL
pair	NULL
HindIII	NULL
fragment	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
(	NULL
a	NULL
gift	NULL
of	NULL
G.	NULL
Crabtree	NULL
,	NULL
Stanford	NULL
University	NULL
,	NULL
Stanford	NULL
,	NULL
CA	NULL
)	NULL
was	NULL
subcloned	NULL
into	NULL
the	NULL
luciferase	NULL
reporter	NULL
plasmid	NULL
pGL2-Enhancer	NULL
(	NULL
Promega	NULL
)	NULL
,	NULL
and	NULL
the	NULL
orientation	NULL
was	NULL
confirmed	NULL
by	NULL
restriction	NULL
enzyme	NULL
mapping	NULL
.	NULL

Three	NULL
base	NULL
pair	NULL
mutations	NULL
in	NULL
individual	NULL
cis-elements	NULL
were	NULL
generated	NULL
by	NULL
recombinant	NULL
PCR	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Three	NULL
base	NULL
pair	NULL
mutations	NULL
were	NULL
selected	NULL
that	NULL
altered	NULL
nucleotides	NULL
known	NULL
to	NULL
be	NULL
critical	NULL
for	NULL
nuclear	NULL
factor	NULL
binding	NULL
(	NULL
see	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

Reaction	NULL
conditions	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
100	NULL
pg	NULL
of	NULL
template	NULL
,	NULL
20	NULL
pmol	NULL
of	NULL
each	NULL
primer	NULL
,	NULL
2	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
and	NULL
200	NULL
uM	NULL
each	NULL
dNTP	NULL
in	NULL
1	NULL
x	NULL
polymerase	NULL
buffer	NULL
with	NULL
1	NULL
unit	NULL
of	NULL
Tag	NULL
polymerase	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
50	NULL
pl	NULL
;	NULL
initial	NULL
denaturation	NULL
at	NULL
95	NULL
Â°C	NULL
for	NULL
1	NULL
min	NULL
;	NULL
amplification	NULL
for	NULL
30	NULL
cycles	NULL
(	NULL
95	NULL
Â°C	NULL
for	NULL
30	NULL
s	NULL
,	NULL
50-53	NULL
Â°C	NULL
(	NULL
depending	NULL
on	NULL
primer	NULL
pair	NULL
)	NULL
for	NULL
30	NULL
s	NULL
,	NULL
and	NULL
72	NULL
Â°C	NULL
for	NULL
1	NULL
min	NULL
)	NULL
;	NULL
and	NULL
final	NULL
extension	NULL
at	NULL
72	NULL
Â°C	NULL
for	NULL
10	NULL
min	NULL
.	NULL

Overhangs	NULL
at	NULL
the	NULL
3'-end	NULL
,	NULL
generated	NULL
by	NULL
Tag	NULL
terminal	NULL
transferase	NULL
activity	NULL
,	NULL
were	NULL
removed	NULL
by	NULL
treatment	NULL
with	NULL
T4	NULL
DNA	NULL
polymerase	NULL
(	NULL
46	NULL
)	NULL
.	NULL

Amplification	NULL
products	NULL
were	NULL
separated	NULL
on	NULL
1.5	NULL
%	NULL
low	NULL
melting	NULL
point	NULL
agarose	NULL
gels	NULL
(	NULL
Sea	NULL
Plaque	NULL
LM	NULL
,	NULL
FMC	NULL
Corp.	NULL
BioProducts	NULL
,	NULL
Rockland	NULL
,	NULL
ME	NULL
)	NULL
;	NULL
bands	NULL
were	NULL
cut	NULL
out	NULL
and	NULL
purified	NULL
;	NULL
and	NULL
the	NULL
two	NULL
halves	NULL
of	NULL
the	NULL
promoter	NULL
generated	NULL
by	NULL
the	NULL
first	NULL
round	NULL
of	NULL
PCR	NULL
were	NULL
then	NULL
recombined	NULL
by	NULL
PCR	NULL
.	NULL

The	NULL
promoters	NULL
were	NULL
subcloned	NULL
back	NULL
into	NULL
pGL2-Enhancer	NULL
,	NULL
and	NULL
the	NULL
sequences	NULL
were	NULL
confirmed	NULL
by	NULL
dideoxy	NULL
sequencing	NULL
(	NULL
U.	NULL
S.	NULL
Biochemical	NULL
Corp.	NULL
)	NULL
.	NULL

Large-scale	NULL
DNA	NULL
preparations	NULL
were	NULL
performed	NULL
by	NULL
selective	NULL
ad-sorption	NULL
to	NULL
resin	NULL
columns	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
(	NULL
QIAGEN	NULL
Inc.	NULL
,	NULL
Chatsworth	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Experiments	NULL
comparing	NULL
different	NULL
promoter	NULL
mutations	NULL
were	NULL
performed	NULL
with	NULL
at	NULL
least	NULL
two	NULL
independent	NULL
plasmid	NULL
preparations	NULL
.	NULL

Experiments	NULL
using	NULL
the	NULL
wild-type	NULL
promoter	NULL
were	NULL
repeated	NULL
with	NULL
more	NULL
than	NULL
five	NULL
independent	NULL
plasmid	NULL
preparations	NULL
.	NULL

Electrophoretic	NULL
Mobility	NULL
Shift	NULL
Assay-Probes	NULL
of	NULL
18-80	NULL
base	NULL
pairs	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10Â°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
IL-2	NULL
Transcription	NULL
in	NULL
Peripheral	NULL
Blood	NULL
Lymphocytes	NULL
5371	NULL
3500	NULL
300	NULL
3000	NULL
-	NULL
a	NULL
2500	NULL
-|-	NULL
200	NULL
2000	NULL
--	NULL
150	NULL
1500	NULL
--	NULL
100	NULL
1000	NULL
500	NULL
1	NULL
1	NULL
1	NULL
.	NULL

50	NULL
12.5	NULL
15	NULL
17.5	NULL
20	NULL
22.5	NULL
25	NULL
time	NULL
(	NULL
hr	NULL
)	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

Optimal	NULL
time	NULL
for	NULL
transfection	NULL
of	NULL
normal	NULL
T	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
cultured	NULL
with	NULL
1	NULL
ug/ml	NULL
PHA	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
and	NULL
then	NULL
transfected	NULL
with	NULL
the	NULL
wild-type	NULL
IL-2	NULL
promoter-luciferase	NULL
reporter	NULL
plasmid	NULL
(	NULL
60	NULL
ug/ml	NULL
)	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

Cells	NULL
were	NULL
restimulated	NULL
with	NULL
PHA	NULL
(	NULL
5	NULL
pg/ml	NULL
)	NULL
and	NULL
PMA	NULL
(	NULL
50	NULL
nM	NULL
)	NULL
and	NULL
harvested	NULL
6	NULL
h	NULL
later	NULL
for	NULL
assay	NULL
of	NULL
luciferase	NULL
.	NULL

Means	NULL
of	NULL
triplicate	NULL
determinations	NULL
are	NULL
shown	NULL
for	NULL
luciferase	NULL
expression	NULL
.	NULL

Standard	NULL
errors	NULL
were	NULL
<	NULL
10	NULL
%	NULL
of	NULL
the	NULL
mean	NULL
.	NULL

Data	NULL
points	NULL
indicate	NULL
relative	NULL
light	NULL
units	NULL
:	NULL
J	NULL
,	NULL
Experiment	NULL
1	NULL
;	NULL
A	NULL
,	NULL
Experiment	NULL
2	NULL
.	NULL

Each	NULL
curve	NULL
is	NULL
an	NULL
independent	NULL
experiment	NULL
.	NULL

(	NULL
synthesized	NULL
by	NULL
the	NULL
Oligonucleotide	NULL
Synthesis	NULL
Facility	NULL
of	NULL
the	NULL
Boyer	NULL
Center	NULL
for	NULL
Molecular	NULL
Medicine	NULL
)	NULL
were	NULL
end-labeled	NULL
using	NULL
[	NULL
y-	NULL
``	NULL
Â°P	NULL
]	NULL
JATP	NULL
(	NULL
Du-Pont	NULL
NEN	NULL
)	NULL
and	NULL
T4	NULL
kinase	NULL
and	NULL
purified	NULL
over	NULL
Sephadex	NULL
G-25	NULL
columns	NULL
.	NULL

Nuclear	NULL
extract	NULL
,	NULL
normalized	NULL
for	NULL
protein	NULL
concentration	NULL
,	NULL
was	NULL
prepared	NULL
from	NULL
PHA-activated	NULL
PBMC	NULL
and	NULL
analyzed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
34	NULL
)	NULL
.	NULL

RESULTS	NULL
Transfection	NULL
of	NULL
Normal	NULL
Peripheral	NULL
Blood	NULL
Lymphocytes-To	NULL
investigate	NULL
the	NULL
regulation	NULL
of	NULL
IL-2	NULL
transcription	NULL
in	NULL
normal	NULL
human	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
have	NULL
developed	NULL
a	NULL
reproducible	NULL
assay	NULL
based	NULL
on	NULL
transient	NULL
transfection	NULL
by	NULL
electroporation	NULL
of	NULL
IL-2	NULL
promoter-luciferase	NULL
reporter	NULL
gene	NULL
constructs	NULL
.	NULL

The	NULL
technique	NULL
is	NULL
sufficiently	NULL
sensitive	NULL
to	NULL
detect	NULL
luciferase	NULL
activity	NULL
in	NULL
as	NULL
few	NULL
as	NULL
8	NULL
X	NULL
10	NULL
%	NULL
cells	NULL
(	NULL
40	NULL
ul	NULL
of	NULL
a	NULL
150-ull	NULL
lysate	NULL
)	NULL
,	NULL
allowing	NULL
routine	NULL
analysis	NULL
of	NULL
microwell	NULL
cultures	NULL
.	NULL

Circulating	NULL
human	NULL
T	NULL
cells	NULL
are	NULL
not	NULL
transfectable	NULL
.	NULL

This	NULL
has	NULL
led	NULL
most	NULL
investigators	NULL
to	NULL
work	NULL
with	NULL
T	NULL
cell	NULL
tumor	NULL
lines	NULL
,	NULL
cells	NULL
that	NULL
may	NULL
not	NULL
accurately	NULL
reflect	NULL
normal	NULL
T	NULL
cell	NULL
behavior	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

However	NULL
,	NULL
we	NULL
have	NULL
found	NULL
that	NULL
the	NULL
T	NULL
cells	NULL
in	NULL
a	NULL
freshly	NULL
isolated	NULL
population	NULL
of	NULL
PBMC	NULL
,	NULL
upon	NULL
stimulation	NULL
with	NULL
a	NULL
concentration	NULL
of	NULL
PHA	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
that	NULL
is	NULL
insufficient	NULL
to	NULL
cause	NULL
significant	NULL
IL-2	NULL
secretion	NULL
,	NULL
pass	NULL
through	NULL
a	NULL
window	NULL
of	NULL
transfection	NULL
competency	NULL
.	NULL

The	NULL
mitogen	NULL
PHA	NULL
polyclonally	NULL
activates	NULL
T	NULL
cells	NULL
by	NULL
binding	NULL
with	NULL
high	NULL
affinity	NULL
to	NULL
the	NULL
TCR	NULL
,	NULL
but	NULL
not	NULL
to	NULL
CD3	NULL
,	NULL
and	NULL
inducing	NULL
calcium	NULL
fluxes	NULL
in	NULL
a	NULL
similar	NULL
manner	NULL
to	NULL
anti-CD3	NULL
or	NULL
anti-TCR	NULL
mAb	NULL
(	NULL
47	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
presentation	NULL
of	NULL
antigen	NULL
by	NULL
MHC	NULL
molecules	NULL
is	NULL
bypassed	NULL
.	NULL

In	NULL
the	NULL
two	NULL
separate	NULL
experiments	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
PBMC	NULL
were	NULL
transfected	NULL
by	NULL
electroporation	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
``	NULL
at	NULL
the	NULL
indicated	NULL
times	NULL
after	NULL
PHA	NULL
stimulation	NULL
;	NULL
luciferase	NULL
was	NULL
assayed	NULL
in	NULL
all	NULL
cases	NULL
after	NULL
restimulation	NULL
for	NULL
6	NULL
h	NULL
with	NULL
PHA	NULL
(	NULL
5	NULL
pg/ml	NULL
)	NULL
plus	NULL
PMA	NULL
(	NULL
50	NULL
nm	NULL
)	NULL
.	NULL

A	NULL
sharp	NULL
peak	NULL
of	NULL
luciferase	NULL
activity	NULL
was	NULL
found	NULL
for	NULL
transfection	NULL
at	NULL
20	NULL
h	NULL
(	NULL
Experiment	NULL
1	NULL
)	NULL
and	NULL
19.5	NULL
h	NULL
(	NULL
Experiment	NULL
2	NULL
)	NULL
.	NULL

We	NULL
have	NULL
found	NULL
consistently	NULL
high	NULL
responses	NULL
when	NULL
cells	NULL
are	NULL
transfected	NULL
during	NULL
this	NULL
window	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
time	NULL
course	NULL
of	NULL
transcription	NULL
mediated	NULL
by	NULL
the	NULL
IL-2	NULL
promoter	NULL
in	NULL
transfected	NULL
normal	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
transfected	NULL
cells	NULL
as	NULL
described	NULL
,	NULL
stimulated	NULL
them	NULL
with	NULL
optimal	NULL
doses	NULL
of	NULL
PHA	NULL
and	NULL
PMA	NULL
,	NULL
and	NULL
then	NULL
assayed	NULL
luciferase	NULL
activity	NULL
and	NULL
secreted	NULL
IL-2	NULL
over	NULL
the	NULL
next	NULL
48	NULL
h.	NULL
As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
onset	NULL
of	NULL
transcription	NULL
is	NULL
rapid	NULL
,	NULL
being	NULL
easily	NULL
detectable	NULL
at	NULL
2	NULL
h.	NULL
Transcription	NULL
peaks	NULL
500	NULL
400	NULL
-	NULL
]	NULL
300	NULL
200	NULL
100	NULL
-	NULL
]	NULL
Time	NULL
(	NULL
hr	NULL
)	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Time	NULL
course	NULL
of	NULL
IL-2	NULL
promoter	NULL
activity	NULL
and	NULL
IL-2	NULL
synthesis	NULL
in	NULL
transfected	NULL
normal	NULL
T	NULL
cells	NULL
.	NULL

Normal	NULL
T	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
wild-type	NULL
IL-2	NULL
promoter-luciferase	NULL
reporter	NULL
plasmid	NULL
(	NULL
60	NULL
ug/ml	NULL
)	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
``	NULL
and	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PHA	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
and	NULL
PMA	NULL
(	NULL
50	NULL
nM	NULL
)	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
before	NULL
harvest	NULL
of	NULL
the	NULL
supernatant	NULL
for	NULL
IL-2	NULL
bioassay	NULL
and	NULL
of	NULL
the	NULL
cells	NULL
for	NULL
luciferase	NULL
assay	NULL
.	NULL

Means	NULL
and	NULL
standard	NULL
errors	NULL
are	NULL
as	NULL
described	NULL
for	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

No	NULL
luciferase	NULL
activity	NULL
above	NULL
background	NULL
levels	NULL
or	NULL
IL-2	NULL
was	NULL
detected	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
PHA	NULL
plus	NULL
PMA	NULL
.	NULL

Data	NULL
are	NULL
representative	NULL
of	NULL
one	NULL
of	NULL
three	NULL
experiments	NULL
with	NULL
similar	NULL
results	NULL
.	NULL

J	NULL
,	NULL
relative	NULL
light	NULL
units	NULL
;	NULL
Â©	NULL
,	NULL
units/	NULL
milliliter	NULL
IL-2	NULL
.	NULL

between	NULL
4	NULL
and	NULL
8	NULL
h	NULL
and	NULL
declines	NULL
rapidly	NULL
to	NULL
~20	NULL
%	NULL
of	NULL
peak	NULL
levels	NULL
by	NULL
18	NULL
h	NULL
and	NULL
then	NULL
more	NULL
slowly	NULL
to	NULL
near	NULL
basal	NULL
levels	NULL
by	NULL
48	NULL
h.	NULL
These	NULL
kinetics	NULL
are	NULL
consistent	NULL
with	NULL
previously	NULL
reported	NULL
kinetics	NULL
of	NULL
mRNA	NULL
appearance	NULL
following	NULL
the	NULL
activation	NULL
of	NULL
resting	NULL
human	NULL
blood	NULL
T	NULL
cells	NULL
(	NULL
5	NULL
)	NULL
and	NULL
parallel	NULL
the	NULL
behavior	NULL
of	NULL
IL-2	NULL
promoter-reporter	NULL
genes	NULL
in	NULL
the	NULL
widely	NULL
used	NULL
T	NULL
cell	NULL
tumor	NULL
line	NULL
,	NULL
Jurkat	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
and	NULL
Ref	NULL
.	NULL

2	NULL
)	NULL
.	NULL

More	NULL
important	NULL
,	NULL
no	NULL
transcription	NULL
was	NULL
detectable	NULL
in	NULL
transfected	NULL
PBMC	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
additional	NULL
stimulation	NULL
,	NULL
despite	NULL
the	NULL
prior	NULL
exposure	NULL
to	NULL
low	NULL
concentrations	NULL
of	NULL
PHA	NULL
.	NULL

Secreted	NULL
IL-2	NULL
was	NULL
measured	NULL
as	NULL
an	NULL
indicator	NULL
of	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
endogenous	NULL
gene	NULL
in	NULL
the	NULL
medium	NULL
of	NULL
the	NULL
same	NULL
cultures	NULL
.	NULL

No	NULL
secreted	NULL
IL-2	NULL
is	NULL
detectable	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
stimulation	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
native	NULL
IL-2	NULL
gene	NULL
is	NULL
not	NULL
active	NULL
as	NULL
a	NULL
result	NULL
of	NULL
the	NULL
prior	NULL
manipulations	NULL
to	NULL
render	NULL
the	NULL
cells	NULL
transfection-competent	NULL
.	NULL

IL-2	NULL
is	NULL
first	NULL
measurable	NULL
in	NULL
the	NULL
medium	NULL
at	NULL
~3-6	NULL
h	NULL
and	NULL
then	NULL
rapidly	NULL
increases	NULL
over	NULL
the	NULL
next	NULL
20	NULL
h.	NULL
Levels	NULL
begin	NULL
to	NULL
plateau	NULL
after	NULL
~24	NULL
h.	NULL
These	NULL
data	NULL
are	NULL
also	NULL
consistent	NULL
with	NULL
previously	NULL
published	NULL
reports	NULL
of	NULL
resting	NULL
T	NULL
cells	NULL
(	NULL
34	NULL
,	NULL
48	NULL
)	NULL
.	NULL

The	NULL
Transfected	NULL
IL-2	NULL
Promoter	NULL
Can	NULL
Only	NULL
Be	NULL
Activated	NULL
in	NULL
T	NULL
Cells-An	NULL
important	NULL
consideration	NULL
in	NULL
interpreting	NULL
our	NULL
data	NULL
is	NULL
that	NULL
we	NULL
transfect	NULL
a	NULL
mixed	NULL
population	NULL
of	NULL
cells	NULL
that	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
T	NULL
cells	NULL
,	NULL
contains	NULL
monocytes	NULL
,	NULL
B	NULL
cells	NULL
,	NULL
natural	NULL
killer	NULL
cells	NULL
,	NULL
and	NULL
dendritic	NULL
cells	NULL
.	NULL

We	NULL
have	NULL
found	NULL
that	NULL
highly	NULL
purified	NULL
T	NULL
cells	NULL
can	NULL
not	NULL
be	NULL
made	NULL
transfection-competent	NULL
by	NULL
treatment	NULL
with	NULL
PHA	NULL
alone	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
to	NULL
determine	NULL
which	NULL
cell	NULL
types	NULL
in	NULL
the	NULL
unfractionated	NULL
PBMC	NULL
population	NULL
are	NULL
expressing	NULL
the	NULL
IL-2	NULL
promoter-luciferase	NULL
construct	NULL
under	NULL
the	NULL
stimulation	NULL
conditions	NULL
we	NULL
use	NULL
,	NULL
we	NULL
sorted	NULL
cells	NULL
by	NULL
FACS	NULL
after	NULL
transfection	NULL
using	NULL
directly	NULL
conjugated	NULL
mouse	NULL
anti-human	NULL
mAb	NULL
specific	NULL
for	NULL
CD4*	NULL
T	NULL
cells	NULL
,	NULL
CD8*	NULL
T	NULL
cells	NULL
,	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
monocytes	NULL
.	NULL

Sorting	NULL
produced	NULL
populations	NULL
of	NULL
>	NULL
99.5	NULL
%	NULL
purity	NULL
.	NULL

When	NULL
assayed	NULL
for	NULL
luciferase	NULL
activity	NULL
,	NULL
only	NULL
CD4*	NULL
T	NULL
cells	NULL
and	NULL
,	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
,	NULL
CD8*	NULL
T	NULL
cells	NULL
expressed	NULL
significant	NULL
activity	NULL
in	NULL
response	NULL
to	NULL
PHA	NULL
plus	NULL
PMA	NULL
.	NULL

An	NULL
equal	NULL
number	NULL
of	NULL
monocytes	NULL
or	NULL
B	NULL
cells	NULL
(	NULL
10-fold	NULL
more	NULL
than	NULL
are	NULL
present	NULL
in	NULL
unfractionated	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cell	NULL
preparations	NULL
)	NULL
expressed	NULL
little	NULL
to	NULL
no	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

In	NULL
additional	NULL
experiments	NULL
,	NULL
we	NULL
confirmed	NULL
the	NULL
complete	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10Â°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
5372	NULL
IL-2	NULL
Transcription	NULL
in	NULL
Peripheral	NULL
Blood	NULL
Lymphocytes	NULL
2500	NULL
2000	NULL
RLU	NULL
1500	NULL
1000	NULL
500	NULL
B	NULL
cells	NULL
Monocytes	NULL
CD4+	NULL
T	NULL
cells	NULL
CD8+	NULL
T	NULL
cells	NULL
Sorted	NULL
population	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

The	NULL
transfected	NULL
IL-2	NULL
promoter	NULL
is	NULL
only	NULL
active	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Total	NULL
PBMC	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
wild-type	NULL
IL-2	NULL
promoter-luciferase	NULL
reporter	NULL
plasmid	NULL
(	NULL
60	NULL
ug/ml	NULL
)	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
``	NULL
and	NULL
then	NULL
sorted	NULL
by	NULL
FACS	NULL
using	NULL
mAbs	NULL
specific	NULL
for	NULL
CD4	NULL
(	NULL
T	NULL
cells	NULL
)	NULL
,	NULL
CD8	NULL
(	NULL
T	NULL
cells	NULL
)	NULL
,	NULL
CD19	NULL
(	NULL
B	NULL
cells	NULL
)	NULL
,	NULL
and	NULL
CD14	NULL
(	NULL
monocytes	NULL
)	NULL
.	NULL

Sorting	NULL
produced	NULL
populations	NULL
of	NULL
>	NULL
99.5	NULL
%	NULL
purity	NULL
.	NULL

IL-2	NULL
secretion	NULL
for	NULL
the	NULL
purified	NULL
stimulated	NULL
populations	NULL
was	NULL
as	NULL
follows	NULL
:	NULL
CD4*	NULL
cells	NULL
,	NULL
29	NULL
units/ml	NULL
;	NULL
CD8	NULL
cells	NULL
,	NULL
2	NULL
units/ml	NULL
;	NULL
and	NULL
B	NULL
cells	NULL
and	NULL
monocytes	NULL
,	NULL
not	NULL
detectable	NULL
.	NULL

Means	NULL
and	NULL
standard	NULL
errors	NULL
are	NULL
as	NULL
described	NULL
for	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Data	NULL
are	NULL
representative	NULL
of	NULL
one	NULL
of	NULL
two	NULL
similar	NULL
experiments	NULL
.	NULL

RLU	NULL
,	NULL
relative	NULL
light	NULL
units	NULL
;	NULL
open	NULL
bars	NULL
,	NULL
unstimulated	NULL
;	NULL
shaded	NULL
bars	NULL
,	NULL
PHA	NULL
+	NULL
PMA	NULL
.	NULL

absence	NULL
of	NULL
luciferase	NULL
activity	NULL
in	NULL
the	NULL
total	NULL
non-CD4*/non-CD8	NULL
*	NULL
cell	NULL
population	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Luciferase	NULL
is	NULL
detectable	NULL
in	NULL
this	NULL
population	NULL
when	NULL
the	NULL
SV40	NULL
promoter	NULL
is	NULL
used	NULL
to	NULL
drive	NULL
reporter	NULL
gene	NULL
expression	NULL
(	NULL
pGL2-Con	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
some	NULL
cells	NULL
in	NULL
the	NULL
non-T	NULL
cell	NULL
population	NULL
are	NULL
transfectable	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
the	NULL
experiment	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
(	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
the	NULL
endogenous	NULL
gene	NULL
,	NULL
measured	NULL
as	NULL
IL-2	NULL
secretion	NULL
,	NULL
was	NULL
also	NULL
only	NULL
active	NULL
in	NULL
the	NULL
T	NULL
cells	NULL
(	NULL
CD4*	NULL
,	NULL
29	NULL
units/ml	NULL
;	NULL
CD8	NULL
*	NULL
,	NULL
2	NULL
units/ml	NULL
;	NULL
and	NULL
monocytes	NULL
,	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
non-T	NULL
cells	NULL
,	NULL
not	NULL
detectable	NULL
)	NULL
.	NULL

These	NULL
data	NULL
confirm	NULL
that	NULL
in	NULL
the	NULL
population	NULL
of	NULL
cells	NULL
used	NULL
in	NULL
our	NULL
experiments	NULL
,	NULL
only	NULL
CD4*	NULL
T	NULL
cells	NULL
and	NULL
,	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
,	NULL
CD8*	NULL
T	NULL
cells	NULL
express	NULL
the	NULL
transfected	NULL
IL-2	NULL
promoter-luciferase	NULL
construct	NULL
.	NULL

Response	NULL
of	NULL
the	NULL
Transfected	NULL
Cells	NULL
to	NULL
Various	NULL
Stimulators	NULL
and	NULL
Costimulators-We	NULL
next	NULL
investigated	NULL
the	NULL
response	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
to	NULL
various	NULL
primary	NULL
(	NULL
T	NULL
cell	NULL
receptor-directed	NULL
)	NULL
and	NULL
secondary	NULL
(	NULL
costimulatory	NULL
)	NULL
signals	NULL
in	NULL
order	NULL
to	NULL
determine	NULL
if	NULL
transfected	NULL
cells	NULL
behave	NULL
similarly	NULL
to	NULL
normal	NULL
un-transfected	NULL
cells	NULL
.	NULL

It	NULL
is	NULL
well	NULL
established	NULL
that	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
,	NULL
the	NULL
IL-2	NULL
promoter	NULL
responds	NULL
well	NULL
to	NULL
a	NULL
combination	NULL
of	NULL
ionomycin	NULL
,	NULL
a	NULL
calcium	NULL
ionophore	NULL
,	NULL
and	NULL
PMA	NULL
,	NULL
but	NULL
only	NULL
weakly	NULL
to	NULL
either	NULL
agent	NULL
alone	NULL
(	NULL
48	NULL
)	NULL
.	NULL

We	NULL
have	NULL
confirmed	NULL
that	NULL
the	NULL
transfected	NULL
promoter	NULL
behaves	NULL
similarly	NULL
(	NULL
Table	NULL
I	NULL
,	NULL
Experiment	NULL
1	NULL
)	NULL
and	NULL
that	NULL
it	NULL
parallels	NULL
the	NULL
response	NULL
of	NULL
the	NULL
endogenous	NULL
gene	NULL
in	NULL
these	NULL
cells	NULL
,	NULL
measured	NULL
as	NULL
secreted	NULL
IL-2	NULL
.	NULL

As	NULL
we	NULL
reported	NULL
above	NULL
,	NULL
both	NULL
the	NULL
lectin	NULL
PHA	NULL
and	NULL
anti-CD3	NULL
mAb	NULL
OKT3	NULL
,	NULL
which	NULL
activate	NULL
T	NULL
cells	NULL
via	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
,	NULL
also	NULL
activate	NULL
transcription	NULL
of	NULL
the	NULL
reporter	NULL
gene	NULL
(	NULL
Table	NULL
I	NULL
,	NULL
Experiment	NULL
2	NULL
)	NULL
.	NULL

PHA	NULL
,	NULL
which	NULL
alone	NULL
provides	NULL
an	NULL
exceptionally	NULL
strong	NULL
signal	NULL
that	NULL
in	NULL
many	NULL
cases	NULL
bypasses	NULL
the	NULL
need	NULL
for	NULL
a	NULL
co-stimulator	NULL
,	NULL
activated	NULL
the	NULL
IL-2	NULL
promoter	NULL
almost	NULL
4-fold	NULL
above	NULL
background	NULL
levels	NULL
and	NULL
induced	NULL
significant	NULL
IL-2	NULL
synthesis	NULL
.	NULL

OKT3	NULL
alone	NULL
,	NULL
however	NULL
,	NULL
only	NULL
weakly	NULL
activated	NULL
the	NULL
promoter	NULL
and	NULL
did	NULL
not	NULL
induce	NULL
IL-2	NULL
synthesis	NULL
.	NULL

CD28	NULL
ligation	NULL
on	NULL
T	NULL
cells	NULL
provides	NULL
strong	NULL
costimulatory	NULL
signals	NULL
,	NULL
but	NULL
antibody	NULL
to	NULL
CD28	NULL
alone	NULL
only	NULL
weakly	NULL
activated	NULL
the	NULL
promoter	NULL
and	NULL
again	NULL
did	NULL
not	NULL
induce	NULL
significant	NULL
IL-2	NULL
synthesis	NULL
.	NULL

However	NULL
,	NULL
anti-CD28	NULL
mAb	NULL
synergized	NULL
with	NULL
TaBuE	NULL
I	NULL
Transfected	NULL
T	NULL
cells	NULL
respond	NULL
to	NULL
several	NULL
different	NULL
primary	NULL
and	NULL
secondary	NULL
activation	NULL
signals	NULL
Transfected	NULL
T	NULL
cells	NULL
(	NULL
8	NULL
X	NULL
10Â°/well	NULL
)	NULL
were	NULL
cultured	NULL
with	NULL
the	NULL
indicated	NULL
reagents	NULL
at	NULL
the	NULL
following	NULL
concentrations	NULL
:	NULL
ionomycin	NULL
(	NULL
200	NULL
ng/ml	NULL
)	NULL
,	NULL
PMA	NULL
(	NULL
10	NULL
nm	NULL
)	NULL
,	NULL
PHA	NULL
(	NULL
6	NULL
pg/ml	NULL
)	NULL
,	NULL
OKT3	NULL
(	NULL
0.5-1	NULL
ug/ml	NULL
)	NULL
,	NULL
mAb	NULL
9.3	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
,	NULL
and	NULL
anti-CD2	NULL
mAbs	NULL
CB6	NULL
+	NULL
GD10	NULL
(	NULL
1	NULL
pg/ml	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
analyzed	NULL
for	NULL
luciferase	NULL
and	NULL
secreted	NULL
IL-2	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

Means	NULL
of	NULL
three	NULL
wells	NULL
are	NULL
shown	NULL
.	NULL

Standard	NULL
errors	NULL
were	NULL
<	NULL
10	NULL
%	NULL
of	NULL
the	NULL
mean	NULL
.	NULL

Data	NULL
are	NULL
representative	NULL
of	NULL
one	NULL
of	NULL
three	NULL
similar	NULL
experiments	NULL
.	NULL

Stimulus	NULL
RLU	NULL
IL-2	NULL
units/ml	NULL
Exp	NULL
.	NULL

1	NULL
None	NULL
48	NULL
0.4	NULL
Ionomycin	NULL
318	NULL
3.2	NULL
PMA	NULL
241	NULL
5.3	NULL
Ionomycin	NULL
+	NULL
PMA	NULL
4963	NULL
16.7	NULL
Exp	NULL
.	NULL

2	NULL
None	NULL
128	NULL
0.3	NULL
PHA	NULL
494	NULL
9.0	NULL
OKT3	NULL
264	NULL
0.6	NULL
mAb	NULL
9.3	NULL
278	NULL
0.3	NULL
OKT3	NULL
+	NULL
mAb	NULL
9.3	NULL
1904	NULL
90.0	NULL
CB6	NULL
+	NULL
GD10	NULL
1295	NULL
11.5	NULL
*	NULL
RLU	NULL
,	NULL
relative	NULL
light	NULL
units	NULL
.	NULL

OKT3	NULL
to	NULL
stimulate	NULL
both	NULL
IL-2	NULL
transcription	NULL
and	NULL
IL-2	NULL
synthesis	NULL
.	NULL

Finally	NULL
,	NULL
it	NULL
has	NULL
been	NULL
previously	NULL
shown	NULL
that	NULL
pairs	NULL
of	NULL
anti-CD2	NULL
mAbs	NULL
can	NULL
activate	NULL
T	NULL
cells	NULL
and	NULL
induce	NULL
IL-2	NULL
synthesis	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
T	NULL
cell	NULL
receptor	NULL
ligation	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
I	NULL
(	NULL
Experiment	NULL
2	NULL
)	NULL
,	NULL
such	NULL
mAbs	NULL
stimulate	NULL
IL-2	NULL
promoter-dependent	NULL
transcription	NULL
in	NULL
transfected	NULL
normal	NULL
cells	NULL
.	NULL

Effect	NULL
of	NULL
B7-positive	NULL
and	NULL
B7-negative	NULL
Accessory	NULL
Cells	NULL
on	NULL
IL-2	NULL
Promoter-dependent	NULL
Transcription-We	NULL
next	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
different	NULL
accessory	NULL
cell	NULL
populations	NULL
on	NULL
costimulation	NULL
of	NULL
IL-2	NULL
promoter-dependent	NULL
transcription	NULL
and	NULL
IL-2	NULL
synthesis	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
.	NULL

We	NULL
compared	NULL
B	NULL
cells	NULL
,	NULL
which	NULL
express	NULL
CD28	NULL
ligands	NULL
,	NULL
with	NULL
EC	NULL
,	NULL
which	NULL
do	NULL
not	NULL
.	NULL

Three	NULL
B	NULL
cell	NULL
lines	NULL
were	NULL
tested	NULL
:	NULL
JY	NULL
,	NULL
an	NULL
Epstein-Barr	NULL
virus-transformed	NULL
line	NULL
;	NULL
Raji	NULL
,	NULL
an	NULL
Epstein-Barr	NULL
virus-positive	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
line	NULL
;	NULL
and	NULL
BJAB	NULL
,	NULL
an	NULL
Epstein-Barr	NULL
virus-negative	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
line	NULL
.	NULL

All	NULL
three	NULL
lines	NULL
expressed	NULL
CD28	NULL
ligands	NULL
,	NULL
and	NULL
results	NULL
were	NULL
similar	NULL
,	NULL
except	NULL
that	NULL
JY	NULL
and	NULL
BJAB	NULL
cells	NULL
were	NULL
generally	NULL
better	NULL
costimulators	NULL
of	NULL
IL-2	NULL
synthesis	NULL
than	NULL
were	NULL
Raji	NULL
cells	NULL
;	NULL
data	NULL
from	NULL
experiments	NULL
with	NULL
JY	NULL
and	NULL
BJAB	NULL
cells	NULL
are	NULL
presented	NULL
.	NULL

EC	NULL
were	NULL
tested	NULL
from	NULL
multiple	NULL
donors	NULL
with	NULL
similar	NULL
results	NULL
,	NULL
and	NULL
representative	NULL
results	NULL
are	NULL
shown	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
both	NULL
B	NULL
cells	NULL
and	NULL
EC	NULL
augmented	NULL
reporter	NULL
gene	NULL
transcription	NULL
in	NULL
PHA-activated	NULL
normal	NULL
T	NULL
cells	NULL
above	NULL
the	NULL
level	NULL
induced	NULL
by	NULL
PHA	NULL
alone	NULL
.	NULL

Over	NULL
several	NULL
experiments	NULL
,	NULL
augmentation	NULL
ranged	NULL
from	NULL
2-	NULL
to	NULL
7-fold	NULL
,	NULL
with	NULL
EC	NULL
and	NULL
B	NULL
cells	NULL
augmenting	NULL
to	NULL
approximately	NULL
the	NULL
same	NULL
level	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
endogenous	NULL
gene	NULL
was	NULL
also	NULL
augmented	NULL
,	NULL
but	NULL
B	NULL
cells	NULL
seemed	NULL
to	NULL
be	NULL
much	NULL
more	NULL
effective	NULL
at	NULL
augmenting	NULL
secreted	NULL
IL-2	NULL
than	NULL
were	NULL
EC	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Both	NULL
B	NULL
cells	NULL
and	NULL
EC	NULL
also	NULL
costimulated	NULL
T	NULL
cells	NULL
purified	NULL
by	NULL
FACS	NULL
.	NULL

In	NULL
this	NULL
case	NULL
,	NULL
little	NULL
or	NULL
no	NULL
luciferase	NULL
or	NULL
secreted	NULL
IL-2	NULL
was	NULL
detectable	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
accessory	NULL
cells	NULL
.	NULL

IL-2	NULL
promoter-dependent	NULL
transcription	NULL
was	NULL
detectable	NULL
in	NULL
both	NULL
highly	NULL
purified	NULL
CD4*	NULL
and	NULL
CD8*	NULL
T	NULL
cells	NULL
stimulated	NULL
by	NULL
accessory	NULL
cells	NULL
,	NULL
and	NULL
both	NULL
cell	NULL
types	NULL
secreted	NULL
IL-2	NULL
.	NULL

CD4*	NULL
T	NULL
cells	NULL
were	NULL
severalfold	NULL
more	NULL
responsive	NULL
than	NULL
CD8*	NULL
T	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
identify	NULL
the	NULL
surface	NULL
molecules	NULL
involved	NULL
in	NULL
costimulation	NULL
by	NULL
B	NULL
cells	NULL
and	NULL
EC	NULL
,	NULL
we	NULL
used	NULL
blocking	NULL
antibodies	NULL
and	NULL
fusion	NULL
proteins	NULL
.	NULL

mAb	NULL
to	NULL
CD2	NULL
blocked	NULL
transcription	NULL
and	NULL
IL-2	NULL
secretion	NULL
induced	NULL
by	NULL
B	NULL
cells	NULL
or	NULL
EC	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
our	NULL
previous	NULL
findings	NULL
(	NULL
5	NULL
)	NULL
,	NULL
anti-CD2	NULL
mAb	NULL
could	NULL
not	NULL
completely	NULL
inhibit	NULL
EC	NULL
costimulation	NULL
.	NULL

Blocking	NULL
of	NULL
B	NULL
cell	NULL
costimulation	NULL
with	NULL
anti-CD2	NULL
mAb	NULL
was	NULL
also	NULL
incomplete	NULL
,	NULL
ranging	NULL
from	NULL
40	NULL
to	NULL
90	NULL
%	NULL
.	NULL

Most	NULL
experiments	NULL
were	NULL
performed	NULL
with	NULL
anti-CD2	NULL
mAb	NULL
TS2/18	NULL
;	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10Â°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
IL-2	NULL
Transcription	NULL
in	NULL
Peripheral	NULL
Blood	NULL
Lymphocytes	NULL
5373	NULL
A	NULL
500	NULL
400	NULL
300	NULL
RLU	NULL
200	NULL
100	NULL
none	NULL
EC	NULL
BJAB	NULL
Stimulating	NULL
cell	NULL
4	NULL
B	NULL
R	NULL
Contro	NULL
!	NULL

{	NULL
J	NULL
s	NULL
a	NULL
Ig	NULL
Control	NULL
CTLA419	NULL
ro	NULL
In	NULL
57711	NULL
none	NULL
EC	NULL
BJAB	NULL
Stimulating	NULL
cell	NULL
Fic	NULL
.	NULL

4	NULL
.	NULL

Different	NULL
accessory	NULL
cells	NULL
costimulate	NULL
through	NULL
different	NULL
surface	NULL
ligands	NULL
.	NULL

Normal	NULL
T	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
wild-type	NULL
IL-2	NULL
promoter-luciferase	NULL
reporter	NULL
plasmid	NULL
(	NULL
60	NULL
pg/ml	NULL
)	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
``	NULL
and	NULL
cultured	NULL
for	NULL
12	NULL
h	NULL
before	NULL
harvest	NULL
of	NULL
the	NULL
supernatant	NULL
for	NULL
IL-2	NULL
bioassay	NULL
and	NULL
of	NULL
the	NULL
cells	NULL
for	NULL
luciferase	NULL
assay	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
PHA	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
and	NULL
cultured	NULL
with	NULL
EC	NULL
(	NULL
1	NULL
x	NULL
10	NULL
``	NULL
/well	NULL
)	NULL
or	NULL
with	NULL
BJAB	NULL
cells	NULL
(	NULL
1	NULL
x	NULL
10*/well	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
control	NULL
mAb	NULL
K16/16	NULL
(	NULL
10	NULL
ug/m1	NULL
)	NULL
,	NULL
anti-CD2	NULL
mAb	NULL
TS2/18	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
,	NULL
control	NULL
Ig	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
,	NULL
or	NULL
CTLA-4-Ig	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
also	NULL
cultured	NULL
with	NULL
PHA	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
accessory	NULL
cells	NULL
or	NULL
blocking	NULL
reagents	NULL
.	NULL

A	NULL
,	NULL
luciferase	NULL
expression	NULL
;	NULL
B	NULL
,	NULL
IL-2	NULL
secretion	NULL
.	NULL

Means	NULL
+	NULL
S.E	NULL
.	NULL

(	NULL
luciferase	NULL
)	NULL
of	NULL
three	NULL
wells	NULL
are	NULL
shown	NULL
.	NULL

Means	NULL
+	NULL
S.D	NULL
.	NULL

(	NULL
IL-2	NULL
)	NULL
are	NULL
calculated	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

Data	NULL
are	NULL
representative	NULL
of	NULL
one	NULL
of	NULL
two	NULL
similar	NULL
experiments	NULL
.	NULL

RLU	NULL
,	NULL
relative	NULL
light	NULL
units	NULL
.	NULL

however	NULL
,	NULL
we	NULL
obtained	NULL
identical	NULL
results	NULL
using	NULL
anti-CD2	NULL
mAbs	NULL
35.1	NULL
and	NULL
TS1/8	NULL
or	NULL
anti-LFA-3	NULL
mAb	NULL
TS2/9	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
role	NULL
of	NULL
CD28-mediated	NULL
signals	NULL
in	NULL
this	NULL
system	NULL
,	NULL
we	NULL
used	NULL
CTLA-4-Ig	NULL
fusion	NULL
protein	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
B7-1	NULL
and	NULL
B7-2	NULL
and	NULL
blocks	NULL
interaction	NULL
with	NULL
their	NULL
ligands	NULL
,	NULL
CD28	NULL
and	NULL
CTLA-4	NULL
.	NULL

Consistent	NULL
with	NULL
our	NULL
previous	NULL
data	NULL
demonstrating	NULL
the	NULL
absence	NULL
of	NULL
CD28	NULL
ligands	NULL
on	NULL
human	NULL
EC	NULL
and	NULL
the	NULL
lack	NULL
of	NULL
effect	NULL
of	NULL
CTLA-4-Ig	NULL
or	NULL
anti-CD28	NULL
mAb	NULL
Fab	NULL
fragments	NULL
on	NULL
EC	NULL
costimulation	NULL
of	NULL
IL-2	NULL
secretion	NULL
(	NULL
49	NULL
)	NULL
,	NULL
CTLA-4-Ig	NULL
did	NULL
not	NULL
block	NULL
EC	NULL
costimulation	NULL
of	NULL
IL-2	NULL
promoter-dependent	NULL
transcription	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
this	NULL
reagent	NULL
did	NULL
not	NULL
block	NULL
IL-2	NULL
secretion	NULL
in	NULL
response	NULL
to	NULL
EC	NULL
.	NULL

In	NULL
sharp	NULL
contrast	NULL
,	NULL
however	NULL
,	NULL
CTLA-4-Ig	NULL
was	NULL
very	NULL
effective	NULL
at	NULL
blocking	NULL
the	NULL
costimulatory	NULL
effects	NULL
of	NULL
CD28	NULL
ligand-bear-ing	NULL
B	NULL
cells	NULL
on	NULL
both	NULL
transcription	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
and	NULL
IL-2	NULL
secretion	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
CTLA-4-Ig	NULL
completely	NULL
inhibited	NULL
the	NULL
augmented	NULL
secretion	NULL
of	NULL
IL-2	NULL
in	NULL
response	NULL
to	NULL
B	NULL
cell	NULL
costimulation	NULL
.	NULL

We	NULL
have	NULL
found	NULL
substantially	NULL
similar	NULL
,	NULL
although	NULL
somewhat	NULL
more	NULL
variable	NULL
,	NULL
results	NULL
using	NULL
anti-CD28	NULL
mAb	NULL
Fab	NULL
fragments	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
IL-2	NULL
Promoter	NULL
Elements	NULL
in	NULL
Human	NULL
Peripheral	NULL
Blood	NULL
T	NULL
Cells-In	NULL
the	NULL
next	NULL
series	NULL
of	NULL
experiments	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
function	NULL
of	NULL
different	NULL
sequence	NULL
elements	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
transfection	NULL
of	NULL
normal	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

Specific	NULL
mutations	NULL
were	NULL
generated	NULL
in	NULL
several	NULL
of	NULL
the	NULL
recognized	NULL
cis-acting	NULL
sites	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
by	NULL
a	NULL
recombinant	NULL
PCR	NULL
technique	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

Three	NULL
base	NULL
pair	NULL
mutations	NULL
were	NULL
selected	NULL
that	NULL
altered	NULL
nucleotides	NULL
known	NULL
to	NULL
be	NULL
critical	NULL
for	NULL
nuclear	NULL
factor	NULL
binding	NULL
.	NULL

This	NULL
approach	NULL
allows	NULL
sequences	NULL
to	NULL
be	NULL
altered	NULL
without	NULL
affecting	NULL
the	NULL
spacing	NULL
between	NULL
individual	NULL
sites	NULL
.	NULL

The	NULL
result	NULL
of	NULL
each	NULL
mutagenesis	NULL
reaction	NULL
was	NULL
confirmed	NULL
by	NULL
sequencing	NULL
,	NULL
and	NULL
the	NULL
functional	NULL
significance	NULL
of	NULL
the	NULL
mutation	NULL
was	NULL
tested	NULL
by	NULL
annealing	NULL
the	NULL
inside	NULL
primers	NULL
and	NULL
using	NULL
this	NULL
double-stranded	NULL
probe	NULL
to	NULL
compete	NULL
for	NULL
protein	NULL
binding	NULL
with	NULL
the	NULL
wild-type	NULL
sequence	NULL
in	NULL
an	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

In	NULL
all	NULL
of	NULL
the	NULL
mutant	NULL
constructs	NULL
tested	NULL
,	NULL
the	NULL
base	NULL
pair	NULL
changes	NULL
we	NULL
introduced	NULL
were	NULL
found	NULL
to	NULL
eliminate	NULL
binding	NULL
of	NULL
the	NULL
cognate	NULL
transcription	NULL
factors	NULL
in	NULL
vitro	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
,	NULL
however	NULL
,	NULL
that	NULL
lack	NULL
of	NULL
binding	NULL
in	NULL
vitro	NULL
does	NULL
not	NULL
necessarily	NULL
rule	NULL
out	NULL
binding	NULL
of	NULL
factors	NULL
in	NULL
vivo	NULL
.	NULL

Representative	NULL
data	NULL
for	NULL
the	NULL
NF-kB	NULL
site	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

In	NULL
this	NULL
experiment	NULL
,	NULL
nuclear	NULL
factor	NULL
bound	NULL
to	NULL
the	NULL
wild-type	NULL
NF-	NULL
Â«	NULL
B	NULL
probe	NULL
and	NULL
was	NULL
competed	NULL
for	NULL
by	NULL
an	NULL
excess	NULL
of	NULL
wild-type	NULL
,	NULL
but	NULL
not	NULL
mutant	NULL
,	NULL
probe	NULL
.	NULL

Each	NULL
of	NULL
the	NULL
mutant	NULL
promoters	NULL
was	NULL
cloned	NULL
upstream	NULL
of	NULL
the	NULL
luciferase	NULL
reporter	NULL
gene	NULL
and	NULL
transfected	NULL
into	NULL
normal	NULL
T	NULL
cells	NULL
along	NULL
with	NULL
either	NULL
pXGH	NULL
(	NULL
a	NULL
growth	NULL
hormone-expressing	NULL
plasmid	NULL
)	NULL
or	NULL
pCMV-B-gal	NULL
(	NULL
a	NULL
B-galactosidase-expressing	NULL
plasmid	NULL
)	NULL
to	NULL
normalize	NULL
for	NULL
transfection	NULL
efficiency	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
TaBuE	NULL
II	NULL
Transcription	NULL
factor-binding	NULL
sites	NULL
in	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
Gen	NULL
means	NULL
)	NULL
Ger	NULL
)	NULL
-	NULL
(	NULL
fine	NULL
)	NULL
[	NULL
sana	NULL
)	NULL
|	NULL
para	NULL
_	NULL
|C	NULL
onrar	NULL
_	NULL
>	NULL
-Goor	NULL
_	NULL
)	NULL
form	NULL
Site	NULL
Position	NULL
Wild	NULL
Type	NULL
Mutant	NULL
dNFAT	NULL
-276	NULL
to	NULL
-286	NULL
GGAGGAAAAAC	NULL
!	NULL

GGCCTAAAAAC	NULL
NFAP-1	NULL
-268	NULL
to	NULL
-275	NULL
TIGTITTCAT	NULL
GAATICAT	NULL
NFxB	NULL
to	NULL
-205	NULL
GGGATTICA	NULL
TCTATITCA	NULL
dAP-1	NULL
-179	NULL
to	NULL
-185	NULL
TCAGTCA	NULL
TCAGCTG	NULL
CD28RE2	NULL
_	NULL
-154	NULL
to	NULL
-161	NULL
GGAATTTCT	NULL
GAGGTTTCT	NULL
pAP-12	NULL
-145	NULL
to	NULL
-152	NULL
TGACTCIT	NULL
GATCTCIT	NULL
pNFAT	NULL
-129	NULL
to	NULL
-139	NULL
AGAGGAAAAAT	NULL
AGATCTAAAAT	NULL
poet	NULL
-70	NULL
to	NULL
-79	NULL
ATGTAAAACA	NULL
ACTAAAAACA	NULL
*	NULL
The	NULL
core	NULL
binding	NULL
sequence	NULL
is	NULL
shown	NULL
.	NULL

The	NULL
target	NULL
sequence	NULL
for	NULL
mutation	NULL
and	NULL
the	NULL
product	NULL
are	NULL
underlined	NULL
.	NULL

*	NULL
These	NULL
sites	NULL
occur	NULL
in	NULL
the	NULL
opposite	NULL
orientation	NULL
in	NULL
the	NULL
promoter	NULL
,	NULL
but	NULL
are	NULL
shown	NULL
here	NULL
as	NULL
the	NULL
reverse	NULL
complement	NULL
sequence	NULL
for	NULL
ease	NULL
of	NULL
comparison	NULL
.	NULL

then	NULL
stimulated	NULL
with	NULL
PHA	NULL
or	NULL
with	NULL
PHA	NULL
plus	NULL
PMA	NULL
and	NULL
harvested	NULL
12	NULL
h	NULL
later	NULL
.	NULL

Levels	NULL
of	NULL
secreted	NULL
IL-2	NULL
produced	NULL
by	NULL
the	NULL
transfected	NULL
cells	NULL
varied	NULL
by	NULL
<	NULL
10	NULL
%	NULL
between	NULL
the	NULL
different	NULL
construct	NULL
pools	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
mutations	NULL
in	NULL
several	NULL
sites	NULL
reduced	NULL
transcription	NULL
in	NULL
PHA-activated	NULL
normal	NULL
T	NULL
cells	NULL
,	NULL
including	NULL
the	NULL
dNFAT	NULL
,	NULL
NF-	NULL
Â«	NULL
B	NULL
,	NULL
and	NULL
pAP-1	NULL
sites	NULL
.	NULL

Over	NULL
several	NULL
experiments	NULL
,	NULL
the	NULL
pAP-1	NULL
site	NULL
was	NULL
consistently	NULL
the	NULL
most	NULL
important	NULL
single	NULL
site	NULL
.	NULL

Mutation	NULL
of	NULL
this	NULL
element	NULL
reduced	NULL
transcription	NULL
by	NULL
85-95	NULL
%	NULL
.	NULL

Mutating	NULL
the	NULL
NFAP-1	NULL
or	NULL
dAP-1	NULL
sites	NULL
generally	NULL
had	NULL
small	NULL
effects	NULL
(	NULL
0-30	NULL
%	NULL
reduction	NULL
)	NULL
,	NULL
and	NULL
in	NULL
several	NULL
experiments	NULL
,	NULL
mutating	NULL
the	NULL
dAP-1	NULL
site	NULL
had	NULL
no	NULL
effect	NULL
.	NULL

Interestingly	NULL
,	NULL
we	NULL
noted	NULL
a	NULL
striking	NULL
difference	NULL
between	NULL
normal	NULL
T	NULL
cells	NULL
activated	NULL
with	NULL
PHA	NULL
plus	NULL
PMA	NULL
and	NULL
those	NULL
activated	NULL
with	NULL
PHA	NULL
alone	NULL
.	NULL

Specifically	NULL
,	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
site	NULL
appeared	NULL
to	NULL
be	NULL
much	NULL
more	NULL
important	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
strong	NULL
protein	NULL
kinase	NULL
C	NULL
activator	NULL
PMA	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

We	NULL
have	NULL
repeated	NULL
this	NULL
experiment	NULL
using	NULL
normal	NULL
T	NULL
cells	NULL
activated	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
OKT3	NULL
and	NULL
find	NULL
the	NULL
same	NULL
pattern	NULL
as	NULL
with	NULL
PHA	NULL
alone	NULL
.	NULL

Under	NULL
these	NULL
conditions	NULL
,	NULL
the	NULL
pAP-1	NULL
and	NULL
NF-	NULL
Â«	NULL
B	NULL
sites	NULL
appear	NULL
to	NULL
be	NULL
the	NULL
dominant	NULL
sites	NULL
,	NULL
and	NULL
there	NULL
are	NULL
significant	NULL
contributions	NULL
from	NULL
the	NULL
NFAT	NULL
and	NULL
NFAP-1	NULL
sites	NULL
as	NULL
well	NULL
as	NULL
the	NULL
pOCT	NULL
site	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

IL-2	NULL
Promoter	NULL
cis-Elements	NULL
Targeted	NULL
by	NULL
Different	NULL
Accessory	NULL
Cells-We	NULL
have	NULL
established	NULL
that	NULL
two	NULL
different	NULL
accessory	NULL
cells	NULL
,	NULL
B	NULL
cells	NULL
and	NULL
EC	NULL
,	NULL
costimulate	NULL
T	NULL
cells	NULL
through	NULL
different	NULL
surface	NULL
molecules	NULL
.	NULL

EC	NULL
engage	NULL
T	NULL
cell	NULL
CD2	NULL
via	NULL
LFA-3	NULL
(	NULL
and/or	NULL
CD59	NULL
)	NULL
,	NULL
but	NULL
do	NULL
not	NULL
stimulate	NULL
through	NULL
CD28	NULL
.	NULL

Conversely	NULL
,	NULL
B	NULL
cells	NULL
stimulate	NULL
T	NULL
cells	NULL
through	NULL
CD2	NULL
and	NULL
CD28	NULL
(	NULL
and/or	NULL
CTLA-4	NULL
)	NULL
.	NULL

Clearly	NULL
,	NULL
both	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10Â°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
5374	NULL
IL-2	NULL
Transcription	NULL
in	NULL
Peripheral	NULL
Blood	NULL
Lymphocytes	NULL
Specific	NULL
Complex	NULL
-	NULL
-im	NULL
Nuclear	NULL
Extract	NULL
-o	NULL
$	NULL
%	NULL
0	NULL
$	NULL
o	NULL
o	NULL
NFkB	NULL
Probe	NULL
+o	NULL
4+	NULL
+	NULL
+	NULL
#	NULL
Competitor	NULL
-o	NULL
--	NULL
WT	NULL
MT	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
analysis	NULL
of	NULL
nuclear	NULL
factor	NULL
binding	NULL
to	NULL
mutant	NULL
NF-	NULL
Â«	NULL
B	NULL
IL-2	NULL
promoter-binding	NULL
site	NULL
.	NULL

The	NULL
inside	NULL
PCR	NULL
primers	NULL
used	NULL
to	NULL
create	NULL
specific	NULL
mutations	NULL
were	NULL
annealed	NULL
to	NULL
form	NULL
a	NULL
double-stranded	NULL
probe	NULL
for	NULL
competition	NULL
.	NULL

The	NULL
wild-type	NULL
probe	NULL
was	NULL
end-labeled	NULL
with	NULL
[	NULL
y-*	NULL
``	NULL
P	NULL
]	NULL
JATP	NULL
and	NULL
incubated	NULL
with	NULL
1-2	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
for	NULL
10	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
100	NULL
ng	NULL
of	NULL
poly	NULL
(	NULL
dl-dC	NULL
)	NULL
and	NULL
a	NULL
50-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
wild-type	NULL
(	NULL
WT	NULL
)	NULL
or	NULL
mutant	NULL
(	NULL
MT	NULL
)	NULL
competitor	NULL
probe	NULL
.	NULL

Bound	NULL
and	NULL
unbound	NULL
probes	NULL
were	NULL
resolved	NULL
on	NULL
6	NULL
%	NULL
nondenaturing	NULL
polyacrylamide	NULL
gels	NULL
,	NULL
which	NULL
were	NULL
then	NULL
dried	NULL
and	NULL
exposed	NULL
to	NULL
storage	NULL
phosphor	NULL
screens	NULL
and	NULL
analyzed	NULL
on	NULL
a	NULL
Molecular	NULL
Dynamics	NULL
PhosphorImager	NULL
.	NULL

accessory	NULL
cells	NULL
may	NULL
also	NULL
stimulate	NULL
through	NULL
other	NULL
pathways	NULL
not	NULL
examined	NULL
in	NULL
this	NULL
report	NULL
.	NULL

We	NULL
next	NULL
wished	NULL
to	NULL
determine	NULL
whether	NULL
these	NULL
different	NULL
accessory	NULL
cells	NULL
activate	NULL
the	NULL
IL-2	NULL
promoter	NULL
via	NULL
the	NULL
same	NULL
combination	NULL
of	NULL
promoter	NULL
cis-elements	NULL
or	NULL
through	NULL
novel	NULL
combinations	NULL
.	NULL

Peripheral	NULL
blood	NULL
T	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
various	NULL
mutant	NULL
promoter	NULL
constructs	NULL
and	NULL
then	NULL
stimulated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
B	NULL
cells	NULL
or	NULL
EC	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7A	NULL
,	NULL
mutations	NULL
of	NULL
the	NULL
various	NULL
cis-elements	NULL
affect	NULL
B	NULL
cell	NULL
and	NULL
EC	NULL
costimulation	NULL
equally	NULL
.	NULL

Specifically	NULL
,	NULL
mutations	NULL
in	NULL
the	NULL
pAP-1	NULL
site	NULL
or	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
site	NULL
were	NULL
most	NULL
effective	NULL
in	NULL
reducing	NULL
transcription	NULL
,	NULL
with	NULL
important	NULL
contributions	NULL
from	NULL
the	NULL
pOCT	NULL
and	NULL
NFAT	NULL
sites	NULL
.	NULL

The	NULL
pNFAT	NULL
site	NULL
was	NULL
consistently	NULL
more	NULL
important	NULL
than	NULL
the	NULL
dNFAT	NULL
site	NULL
,	NULL
although	NULL
mutations	NULL
in	NULL
both	NULL
were	NULL
additive	NULL
.	NULL

Interestingly	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
CD28RE	NULL
did	NULL
not	NULL
affect	NULL
costimulation	NULL
by	NULL
the	NULL
CD28	NULL
ligand-positive	NULL
B	NULL
cells	NULL
,	NULL
an	NULL
unexpected	NULL
result	NULL
given	NULL
the	NULL
previous	NULL
identification	NULL
of	NULL
this	NULL
site	NULL
as	NULL
the	NULL
target	NULL
of	NULL
CD28-mediated	NULL
signaling	NULL
.	NULL

Over	NULL
several	NULL
experiments	NULL
,	NULL
using	NULL
B	NULL
cells	NULL
as	NULL
costimulators	NULL
,	NULL
we	NULL
consistently	NULL
failed	NULL
to	NULL
see	NULL
a	NULL
reduction	NULL
in	NULL
transcription	NULL
as	NULL
a	NULL
result	NULL
of	NULL
mutating	NULL
this	NULL
site	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
repeated	NULL
these	NULL
experiments	NULL
to	NULL
compare	NULL
defined	NULL
costimulatory	NULL
antibodies	NULL
with	NULL
accessory	NULL
cells	NULL
.	NULL

We	NULL
used	NULL
an	NULL
activating	NULL
pair	NULL
of	NULL
anti-CD2	NULL
mAbs	NULL
or	NULL
an	NULL
anti-CD28	NULL
mAb	NULL
in	NULL
conjunction	NULL
with	NULL
an	NULL
anti-CD3	NULL
mAb	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
and	NULL
compared	NULL
these	NULL
to	NULL
EC	NULL
and	NULL
B	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7C	NULL
)	NULL
.	NULL

Again	NULL
,	NULL
the	NULL
same	NULL
combination	NULL
of	NULL
cis-regulatory	NULL
elements	NULL
was	NULL
critical	NULL
in	NULL
each	NULL
case	NULL
.	NULL

The	NULL
pAP-1	NULL
and	NULL
NF-	NULL
Â«	NULL
B	NULL
sites	NULL
were	NULL
most	NULL
important	NULL
for	NULL
CD2-	NULL
,	NULL
CD28-	NULL
,	NULL
or	NULL
accessory	NULL
cell-mediated	NULL
costimulation	NULL
.	NULL

The	NULL
pOCT	NULL
and	NULL
NFAT	NULL
sites	NULL
also	NULL
contributed	NULL
,	NULL
along	NULL
with	NULL
the	NULL
NFAP-1	NULL
site	NULL
.	NULL

Interestingly	NULL
,	NULL
although	NULL
the	NULL
CD28RE	NULL
mutation	NULL
did	NULL
not	NULL
affect	NULL
CD2-	NULL
,	NULL
B	NULL
cell-	NULL
,	NULL
or	NULL
EC-mediated	NULL
costimulation	NULL
,	NULL
it	NULL
did	NULL
have	NULL
a	NULL
variable	NULL
effect	NULL
on	NULL
anti-CD28	NULL
mAb-mediated	NULL
transcription	NULL
:	NULL
in	NULL
three	NULL
of	NULL
five	NULL
experiments	NULL
,	NULL
we	NULL
saw	NULL
a	NULL
25-50	NULL
%	NULL
reduction	NULL
in	NULL
transcription	NULL
from	NULL
the	NULL
mutant	NULL
CD28RE	NULL
promoter	NULL
compared	NULL
with	NULL
the	NULL
wild-type	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

1.5	NULL
1â	NULL
Normalized	NULL
RLU	NULL
0.5	NULL
0â	NULL
bo	NULL
b	NULL
ov	NULL
Â©	NULL
tot	NULL
ko	NULL
ok	NULL
oh	NULL
%	NULL
fo	NULL
%	NULL
&	NULL
%	NULL
Â£	NULL
&	NULL
f	NULL
}	NULL
z	NULL
f	NULL
zZ	NULL
S	NULL
$	NULL
%	NULL
z	NULL
z	NULL
4	NULL
32	NULL
Â°	NULL
Z	NULL
t	NULL
g	NULL
#	NULL
2	NULL
$	NULL
Â¢	NULL
E	NULL
r	NULL
E	NULL
E	NULL
g	NULL
3	NULL
E	NULL
3	NULL
construct	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

Effect	NULL
of	NULL
nuclear	NULL
factor-binding	NULL
site	NULL
mutations	NULL
on	NULL
IL-2	NULL
transcription	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
wild-type	NULL
(	NULL
WT	NULL
)	NULL
and	NULL
mutant	NULL
(	NULL
mt	NULL
)	NULL
IL-2	NULL
promoter-luciferase	NULL
reporter	NULL
plasmids	NULL
(	NULL
60	NULL
pg/ml	NULL
!	NULL
)	NULL

along	NULL
with	NULL
a	NULL
B-galactosidase-expressing	NULL
control	NULL
plasmid	NULL
(	NULL
10	NULL
pg/ml	NULL
)	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
``	NULL
and	NULL
cultured	NULL
for	NULL
12	NULL
h	NULL
before	NULL
harvest	NULL
of	NULL
the	NULL
supernatant	NULL
for	NULL
IL-2	NULL
bioassay	NULL
and	NULL
of	NULL
the	NULL
cells	NULL
for	NULL
B-galactosidase	NULL
and	NULL
luciferase	NULL
assay	NULL
.	NULL

Transfected	NULL
normal	NULL
T	NULL
cells	NULL
(	NULL
pretreated	NULL
with	NULL
1	NULL
ug/ml	NULL
PHA	NULL
)	NULL
were	NULL
restimulated	NULL
with	NULL
PHA	NULL
(	NULL
5	NULL
pg/ml	NULL
)	NULL
and	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
!	NULL
)	NULL

(	NULL
closed	NULL
bars	NULL
)	NULL
or	NULL
with	NULL
PHA	NULL
alone	NULL
(	NULL
open	NULL
bars	NULL
)	NULL
.	NULL

Luciferase	NULL
expression	NULL
for	NULL
the	NULL
different	NULL
constructs	NULL
was	NULL
normalized	NULL
to	NULL
B-galactosidase	NULL
,	NULL
and	NULL
then	NULL
corrected	NULL
expression	NULL
of	NULL
each	NULL
construct	NULL
was	NULL
normalized	NULL
to	NULL
the	NULL
wild	NULL
type	NULL
.	NULL

Uncorrected	NULL
wild-type	NULL
expression	NULL
for	NULL
normal	NULL
T	NULL
cells	NULL
was	NULL
245	NULL
relative	NULL
light	NULL
units	NULL
(	NULL
RLU	NULL
)	NULL
.	NULL

Data	NULL
are	NULL
representative	NULL
of	NULL
one	NULL
of	NULL
three	NULL
similar	NULL
experiments	NULL
.	NULL

d/pNFAT	NULL
is	NULL
a	NULL
construct	NULL
with	NULL
both	NULL
NFAT	NULL
sites	NULL
mutated	NULL
.	NULL

Comparison	NULL
of	NULL
Normal	NULL
T	NULL
Cells	NULL
with	NULL
Jurkat	NULL
Tumor	NULL
Cells-The	NULL
Jurkat	NULL
T	NULL
cell	NULL
tumor	NULL
line	NULL
is	NULL
the	NULL
most	NULL
widely	NULL
used	NULL
model	NULL
for	NULL
study	NULL
of	NULL
human	NULL
transcriptional	NULL
regulation	NULL
of	NULL
IL-2	NULL
.	NULL

Typically	NULL
,	NULL
these	NULL
cells	NULL
are	NULL
stimulated	NULL
with	NULL
PHA	NULL
plus	NULL
PMA	NULL
;	NULL
activation	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
PMA	NULL
is	NULL
ineffective	NULL
.	NULL

In	NULL
the	NULL
experiments	NULL
reported	NULL
here	NULL
,	NULL
we	NULL
also	NULL
pretreated	NULL
the	NULL
Jurkat	NULL
cells	NULL
with	NULL
low	NULL
doses	NULL
of	NULL
PHA	NULL
so	NULL
that	NULL
the	NULL
conditions	NULL
were	NULL
comparable	NULL
to	NULL
those	NULL
used	NULL
for	NULL
normal	NULL
cells	NULL
,	NULL
although	NULL
pilot	NULL
experiments	NULL
established	NULL
that	NULL
this	NULL
treatment	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
observed	NULL
results	NULL
.	NULL

Results	NULL
with	NULL
Jurkat	NULL
T	NULL
cells	NULL
differed	NULL
in	NULL
several	NULL
respects	NULL
from	NULL
those	NULL
observed	NULL
with	NULL
normal	NULL
T	NULL
cells	NULL
examined	NULL
in	NULL
parallel	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

Most	NULL
striking	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
dNFAT	NULL
and	NULL
NFAP-1	NULL
sites	NULL
was	NULL
consistently	NULL
much	NULL
more	NULL
effective	NULL
at	NULL
reducing	NULL
transcription	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
up	NULL
to	NULL
75	NULL
%	NULL
)	NULL
than	NULL
were	NULL
these	NULL
same	NULL
mutations	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
(	NULL
0-50	NULL
%	NULL
)	NULL
.	NULL

These	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
previously	NULL
published	NULL
reports	NULL
detailing	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
dNFAT	NULL
site	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
21	NULL
,	NULL
27	NULL
,	NULL
50	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
site	NULL
is	NULL
without	NULL
effect	NULL
,	NULL
but	NULL
this	NULL
may	NULL
be	NULL
attributable	NULL
to	NULL
the	NULL
need	NULL
to	NULL
use	NULL
PMA	NULL
to	NULL
activate	NULL
the	NULL
cells	NULL
(	NULL
see	NULL
above	NULL
)	NULL
.	NULL

DISCUSSION	NULL
Transfected	NULL
normal	NULL
human	NULL
T	NULL
cells	NULL
provide	NULL
a	NULL
sensitive	NULL
and	NULL
physiologically	NULL
relevant	NULL
model	NULL
for	NULL
studying	NULL
cytokine	NULL
transcription	NULL
.	NULL

We	NULL
have	NULL
used	NULL
this	NULL
system	NULL
to	NULL
analyze	NULL
the	NULL
regulation	NULL
of	NULL
IL-2	NULL
synthesis	NULL
and	NULL
find	NULL
that	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
is	NULL
inducible	NULL
in	NULL
these	NULL
cells	NULL
and	NULL
responds	NULL
to	NULL
the	NULL
same	NULL
primary	NULL
and	NULL
costimulatory	NULL
signals	NULL
as	NULL
the	NULL
endogenous	NULL
promoter	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
find	NULL
that	NULL
the	NULL
regulation	NULL
of	NULL
IL-2	NULL
transcription	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
differs	NULL
from	NULL
that	NULL
in	NULL
the	NULL
tumor	NULL
cell	NULL
line	NULL
Jurkat	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
transfected	NULL
normal	NULL
human	NULL
T	NULL
cells	NULL
respond	NULL
to	NULL
costimulation	NULL
by	NULL
different	NULL
APC	NULL
and	NULL
that	NULL
B	NULL
cells	NULL
and	NULL
EC	NULL
signal	NULL
through	NULL
different	NULL
costimulatory	NULL
ligands	NULL
,	NULL
but	NULL
target	NULL
the	NULL
same	NULL
cis-acting	NULL
elements	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10Â°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
IL-2	NULL
Transcription	NULL
in	NULL
Peripheral	NULL
Blood	NULL
Lymphocytes	NULL
5375	NULL
A	NULL
2500	NULL
PHA	NULL
2000	NULL
-	NULL
EC+PHA	NULL
JY+PHA	NULL
1500	NULL
7	NULL
RLU	NULL
1000	NULL
500	NULL
o	NULL
-	NULL
21	NULL
t	NULL
lt	NULL
T	NULL
Â©	NULL
t	NULL
c	NULL
T	NULL
E	NULL
E	NULL
i	NULL
=	NULL
f	NULL
&	NULL
e	NULL
&	NULL
Â§	NULL
i	NULL
fof	NULL
8	NULL
%	NULL
IC	NULL
Z	NULL
G	NULL
O	NULL
a	NULL
.	NULL

Z	NULL
Z	NULL
a.	NULL
po	NULL
2	NULL
Eos	NULL
&	NULL
e	NULL
2	NULL
Â§	NULL
5	NULL
3	NULL
E	NULL
3	NULL
bs	NULL
3	NULL
pS	NULL
Construct	NULL
B	NULL
3000	NULL
none	NULL
CBE	NULL
+	NULL
GD10	NULL
2000	NULL
-	NULL
OKT3	NULL
+	NULL
9.3	NULL
RLU	NULL
1000	NULL
-O.-	NULL
B	NULL
I	NULL
E	NULL
I	NULL
ko	NULL
ob	NULL
B	NULL
d	NULL
,	NULL
i	NULL
a.	NULL
o	NULL
,	NULL
3	NULL
o	NULL
go	NULL
3	NULL
93	NULL
Â§	NULL
<	NULL
4	NULL
}	NULL
Q	NULL
O	NULL
z	NULL
i-	NULL
-	NULL
8	NULL
|-	NULL
o	NULL
a	NULL
s	NULL
g	NULL
=	NULL
E	NULL
2	NULL
&	NULL
k	NULL
$	NULL
5	NULL
i	NULL
3	NULL
3	NULL
Construct	NULL
C	NULL
2000	NULL
none	NULL
EC	NULL
+	NULL
OKT3	NULL
1500	NULL
-I	NULL
JY	NULL
+	NULL
OKT3	NULL
RLU	NULL
1000	NULL
500	NULL
=	NULL
Oâ	NULL
MT	NULL
dNFAT	NULL
MT	NULL
NFAP-1	NULL
MT	NULL
pAP-1	NULL
MT	NULL
pNFAT	NULL
MT	NULL
pOCt	NULL
Io	NULL
E	NULL
A	NULL
.	NULL

So	NULL
&	NULL
2	NULL
a	NULL
Co	NULL
o	NULL
=	NULL
p	NULL
3	NULL
Construct	NULL
Fic	NULL
.	NULL

7	NULL
.	NULL

Effect	NULL
of	NULL
nuclear	NULL
factor-binding	NULL
site	NULL
mutations	NULL
on	NULL
IL-2	NULL
transcription	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
costimulated	NULL
by	NULL
EC	NULL
,	NULL
JY	NULL
B	NULL
cells	NULL
,	NULL
or	NULL
costimulatory	NULL
antibodies	NULL
.	NULL

Cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
wild	NULL
MT	NULL
d/pNFAT	NULL
1.5	NULL
1â	NULL
Normalized	NULL
RLU	NULL
0.5	NULL
0â	NULL
5	NULL
k	NULL
I	NULL
$	NULL
I	NULL
I	NULL
R	NULL
k	NULL
B	NULL
to	NULL
&	NULL
E	NULL
%	NULL
4	NULL
&	NULL
&	NULL
g	NULL
s	NULL
Â§	NULL
2	NULL
$	NULL
$	NULL
f	NULL
i	NULL
:	NULL
a	NULL
Eweâï¬\	NULL
``	NULL
'	NULL
E	NULL
â¬	NULL
EEEEE	NULL
construct	NULL
Fic	NULL
.	NULL

8	NULL
.	NULL

Comparison	NULL
of	NULL
nuclear	NULL
factor-binding	NULL
site	NULL
mutations	NULL
on	NULL
IL-2	NULL
transcription	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
versus	NULL
Jurkat	NULL
tumor	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
normal	NULL
T	NULL
cell	NULL
results	NULL
are	NULL
the	NULL
same	NULL
as	NULL
those	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
for	NULL
cells	NULL
activated	NULL
by	NULL
PHA	NULL
plus	NULL
PMA	NULL
.	NULL

The	NULL
conditions	NULL
for	NULL
transfection	NULL
and	NULL
activation	NULL
of	NULL
Jurkat	NULL
cells	NULL
are	NULL
the	NULL
same	NULL
as	NULL
for	NULL
normal	NULL
T	NULL
cells	NULL
.	NULL

Uncorrected	NULL
wild-type	NULL
expression	NULL
for	NULL
normal	NULL
T	NULL
cells	NULL
was	NULL
245	NULL
relative	NULL
light	NULL
units	NULL
(	NULL
RLU	NULL
)	NULL
,	NULL
and	NULL
that	NULL
for	NULL
Jurkat	NULL
cells	NULL
was	NULL
67,599	NULL
relative	NULL
light	NULL
units	NULL
.	NULL

Data	NULL
are	NULL
representative	NULL
of	NULL
one	NULL
of	NULL
three	NULL
similar	NULL
experiments	NULL
.	NULL

d/pNFAT	NULL
is	NULL
a	NULL
construct	NULL
with	NULL
both	NULL
NFAT	NULL
sites	NULL
mutated	NULL
.	NULL

WT	NULL
,	NULL
wild-type	NULL
construct	NULL
;	NULL
mt	NULL
,	NULL
mutant	NULL
construct	NULL
;	NULL
open	NULL
bars	NULL
,	NULL
normal	NULL
T	NULL
cells	NULL
+	NULL
PHA	NULL
+	NULL
PMA	NULL
;	NULL
closed	NULL
bars	NULL
,	NULL
Jurkat	NULL
tumor	NULL
T	NULL
cells	NULL
(	NULL
JK	NULL
)	NULL
+	NULL
PHA	NULL
+	NULL
PMA	NULL
.	NULL

In	NULL
the	NULL
experiments	NULL
described	NULL
here	NULL
,	NULL
we	NULL
have	NULL
transfected	NULL
a	NULL
mixed	NULL
population	NULL
of	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
by	NULL
use	NULL
of	NULL
FACS	NULL
of	NULL
transfected	NULL
cells	NULL
,	NULL
we	NULL
have	NULL
determined	NULL
that	NULL
only	NULL
T	NULL
cells	NULL
express	NULL
the	NULL
luciferase	NULL
reporter	NULL
gene	NULL
and	NULL
that	NULL
only	NULL
T	NULL
cells	NULL
secrete	NULL
IL-2	NULL
.	NULL

CD4*	NULL
T	NULL
cells	NULL
are	NULL
severalfold	NULL
more	NULL
active	NULL
in	NULL
this	NULL
respect	NULL
than	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
this	NULL
system	NULL
,	NULL
the	NULL
IL-2	NULL
promoter	NULL
is	NULL
highly	NULL
T	NULL
cell-specific	NULL
.	NULL

A	NULL
potential	NULL
limitation	NULL
of	NULL
these	NULL
studies	NULL
is	NULL
that	NULL
we	NULL
must	NULL
culture	NULL
normal	NULL
T	NULL
cells	NULL
with	NULL
1	NULL
ug/ml	NULL
PHA	NULL
to	NULL
induce	NULL
transfection	NULL
competence	NULL
.	NULL

Under	NULL
these	NULL
conditions	NULL
,	NULL
there	NULL
is	NULL
no	NULL
significant	NULL
IL-2	NULL
production	NULL
.	NULL

IL-2	NULL
is	NULL
required	NULL
for	NULL
progression	NULL
of	NULL
T	NULL
cells	NULL
from	NULL
G	NULL
;	NULL
to	NULL
S	NULL
phase	NULL
(	NULL
2	NULL
)	NULL
.	NULL

This	NULL
treatment	NULL
,	NULL
therefore	NULL
,	NULL
probably	NULL
moves	NULL
the	NULL
T	NULL
cells	NULL
from	NULL
G	NULL
,	NULL
to	NULL
G	NULL
,	NULL
.	NULL

However	NULL
,	NULL
several	NULL
observations	NULL
demonstrate	NULL
that	NULL
transfected	NULL
normal	NULL
T	NULL
cells	NULL
still	NULL
respond	NULL
similarly	NULL
to	NULL
freshly	NULL
isolated	NULL
resting	NULL
T	NULL
cells	NULL
.	NULL

1	NULL
)	NULL
Once	NULL
transfected	NULL
,	NULL
the	NULL
cells	NULL
do	NULL
not	NULL
secrete	NULL
IL-2	NULL
or	NULL
transcribe	NULL
the	NULL
reporter	NULL
gene	NULL
unless	NULL
further	NULL
activated	NULL
with	NULL
mitogen	NULL
.	NULL

2	NULL
)	NULL
The	NULL
kinetics	NULL
of	NULL
the	NULL
transcriptional	NULL
response	NULL
parallel	NULL
those	NULL
of	NULL
the	NULL
endogenous	NULL
IL-2	NULL
gene	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
.	NULL

3	NULL
)	NULL
OKT3	NULL
signals	NULL
are	NULL
weak	NULL
and	NULL
must	NULL
be	NULL
costimulated	NULL
by	NULL
anti-CD28	NULL
mAb	NULL
to	NULL
activate	NULL
optimal	NULL
IL-2	NULL
transcription	NULL
.	NULL

4	NULL
)	NULL
The	NULL
cells	NULL
can	NULL
receive	NULL
costimulation	NULL
from	NULL
APC	NULL
.	NULL

5	NULL
)	NULL
Costimu-	NULL
type	NULL
(	NULL
WT	NULL
)	NULL
and	NULL
mutant	NULL
(	NULL
MT	NULL
)	NULL
IL-2	NULL
promoter-luciferase	NULL
reporter	NULL
plasmids	NULL
(	NULL
50	NULL
ug/m	NULL
!	NULL
)	NULL

along	NULL
with	NULL
pXGH	NULL
or	NULL
pCMV-B-gal	NULL
(	NULL
10	NULL
pg/m	NULL
!	NULL
)	NULL

as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
``	NULL
and	NULL
cultured	NULL
for	NULL
12	NULL
h	NULL
before	NULL
harvest	NULL
.	NULL

A	NULL
,	NULL
transfected	NULL
T	NULL
cells	NULL
were	NULL
cultured	NULL
with	NULL
5	NULL
ug/ml	NULL
PHA	NULL
either	NULL
alone	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
EC	NULL
(	NULL
1	NULL
x	NULL
10*/well	NULL
)	NULL
or	NULL
JY	NULL
cells	NULL
(	NULL
1	NULL
x	NULL
10*/well	NULL
)	NULL
.	NULL

Data	NULL
are	NULL
representative	NULL
of	NULL
one	NULL
of	NULL
six	NULL
similar	NULL
experiments	NULL
.	NULL

B	NULL
,	NULL
transfected	NULL
T	NULL
cells	NULL
were	NULL
cultured	NULL
either	NULL
alone	NULL
or	NULL
with	NULL
anti-CD2	NULL
mAbs	NULL
CB6	NULL
and	NULL
GD10	NULL
(	NULL
1	NULL
ug/m	NULL
!	NULL

1	NULL
)	NULL
or	NULL
anti-CD3	NULL
mAb	NULL
OKT3	NULL
(	NULL
0.5-1	NULL
pg/ml	NULL
)	NULL
plus	NULL
mAb	NULL
9.3	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
.	NULL

Data	NULL
are	NULL
representative	NULL
of	NULL
one	NULL
of	NULL
two	NULL
similar	NULL
experiments	NULL
.	NULL

C	NULL
,	NULL
transfected	NULL
T	NULL
cells	NULL
were	NULL
cultured	NULL
either	NULL
alone	NULL
or	NULL
with	NULL
OKT3	NULL
(	NULL
0.5-1	NULL
pg/ml	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
EC	NULL
(	NULL
1	NULL
x	NULL
10*/well	NULL
)	NULL
or	NULL
JY	NULL
cells	NULL
(	NULL
1	NULL
x	NULL
10*/well	NULL
)	NULL
.	NULL

Data	NULL
are	NULL
representative	NULL
of	NULL
one	NULL
of	NULL
two	NULL
similar	NULL
experiments	NULL
.	NULL

Shown	NULL
are	NULL
means	NULL
+	NULL
S.E	NULL
.	NULL

of	NULL
triplicate	NULL
determinations	NULL
.	NULL

IL-2	NULL
in	NULL
the	NULL
medium	NULL
did	NULL
not	NULL
vary	NULL
by	NULL
more	NULL
than	NULL
10	NULL
%	NULL
between	NULL
pools	NULL
of	NULL
cells	NULL
transfected	NULL
with	NULL
each	NULL
of	NULL
the	NULL
constructs	NULL
.	NULL

RLU	NULL
,	NULL
relative	NULL
light	NULL
units	NULL
.	NULL

610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10Â°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
5376	NULL
IL-2	NULL
Transcription	NULL
in	NULL
Peripheral	NULL
Blood	NULL
Lymphocytes	NULL
lation	NULL
can	NULL
be	NULL
blocked	NULL
by	NULL
mAb	NULL
to	NULL
CD2	NULL
or	NULL
fusion	NULL
proteins	NULL
that	NULL
bind	NULL
CD28	NULL
ligands	NULL
.	NULL

The	NULL
IL-2	NULL
promoter	NULL
contains	NULL
numerous	NULL
transcription	NULL
factor-binding	NULL
sites	NULL
.	NULL

Several	NULL
of	NULL
these	NULL
have	NULL
been	NULL
shown	NULL
by	NULL
genomic	NULL
footprinting	NULL
to	NULL
bind	NULL
proteins	NULL
,	NULL
and	NULL
some	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
functional	NULL
by	NULL
transfection	NULL
of	NULL
mutant	NULL
reporter	NULL
gene	NULL
constructs	NULL
(	NULL
21	NULL
,	NULL
24	NULL
,	NULL
28	NULL
,	NULL
35	NULL
,	NULL
39	NULL
,	NULL
41	NULL
,	NULL
50	NULL
)	NULL
.	NULL

However	NULL
,	NULL
nearly	NULL
all	NULL
of	NULL
these	NULL
studies	NULL
have	NULL
been	NULL
done	NULL
in	NULL
tumor	NULL
cell	NULL
lines	NULL
,	NULL
with	NULL
the	NULL
assumption	NULL
that	NULL
gene	NULL
regulation	NULL
in	NULL
these	NULL
cells	NULL
would	NULL
be	NULL
identical	NULL
to	NULL
that	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
there	NULL
is	NULL
little	NULL
or	NULL
no	NULL
direct	NULL
information	NULL
as	NULL
to	NULL
which	NULL
sites	NULL
are	NULL
relevant	NULL
for	NULL
IL-2	NULL
transcription	NULL
in	NULL
normal	NULL
nontransformed	NULL
T	NULL
cells	NULL
.	NULL

A	NULL
step	NULL
toward	NULL
analysis	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
in	NULL
vivo	NULL
has	NULL
been	NULL
made	NULL
by	NULL
the	NULL
generation	NULL
of	NULL
transgenic	NULL
mice	NULL
with	NULL
the	NULL
IL-2	NULL
promoter	NULL
driving	NULL
lacZ	NULL
expression	NULL
(	NULL
51	NULL
)	NULL
.	NULL

This	NULL
study	NULL
suggests	NULL
that	NULL
differences	NULL
between	NULL
normal	NULL
cells	NULL
and	NULL
tumor	NULL
cells	NULL
do	NULL
exist	NULL
.	NULL

In	NULL
Jurkat	NULL
cells	NULL
,	NULL
for	NULL
example	NULL
,	NULL
we	NULL
confirm	NULL
that	NULL
the	NULL
dNFAT	NULL
site	NULL
is	NULL
critical	NULL
for	NULL
inducible	NULL
transcription	NULL
regulated	NULL
by	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
50	NULL
)	NULL
.	NULL

The	NULL
nearby	NULL
sequence	NULL
we	NULL
have	NULL
designated	NULL
as	NULL
NFAP-1	NULL
was	NULL
equally	NULL
important	NULL
.	NULL

In	NULL
normal	NULL
T	NULL
cells	NULL
,	NULL
however	NULL
,	NULL
these	NULL
sites	NULL
were	NULL
far	NULL
less	NULL
important	NULL
.	NULL

We	NULL
found	NULL
instead	NULL
that	NULL
the	NULL
pNFAT	NULL
site	NULL
is	NULL
more	NULL
important	NULL
than	NULL
the	NULL
dNFAT	NULL
site	NULL
and	NULL
that	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
and	NULL
pAP-1	NULL
sites	NULL
are	NULL
quan-titatively	NULL
most	NULL
important	NULL
.	NULL

Mutation	NULL
of	NULL
either	NULL
element	NULL
almost	NULL
completely	NULL
blocked	NULL
transcription	NULL
in	NULL
PHA-stimulated	NULL
normal	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
recent	NULL
generation	NULL
of	NULL
an	NULL
NF-kB	NULL
p50	NULL
knockout	NULL
mouse	NULL
suggests	NULL
that	NULL
the	NULL
NF-kB	NULL
site	NULL
may	NULL
be	NULL
important	NULL
in	NULL
vivo	NULL
as	NULL
T	NULL
cells	NULL
from	NULL
these	NULL
mice	NULL
failed	NULL
to	NULL
proliferate	NULL
to	NULL
mitogenic	NULL
signals	NULL
,	NULL
suggesting	NULL
a	NULL
defect	NULL
in	NULL
the	NULL
generation	NULL
of	NULL
IL-2	NULL
(	NULL
52	NULL
)	NULL
.	NULL

Surprisingly	NULL
,	NULL
we	NULL
found	NULL
a	NULL
difference	NULL
in	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
site	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
PMA	NULL
.	NULL

Specifically	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PMA	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
NF-kB	NULL
site	NULL
reduced	NULL
transcription	NULL
by	NULL
<	NULL
50	NULL
%	NULL
.	NULL

However	NULL
,	NULL
when	NULL
normal	NULL
T	NULL
cells	NULL
were	NULL
activated	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
PMA	NULL
,	NULL
by	NULL
PHA	NULL
,	NULL
by	NULL
OKT3	NULL
plus	NULL
anti-CD28	NULL
mAb	NULL
,	NULL
or	NULL
by	NULL
pairs	NULL
of	NULL
anti-CD2	NULL
mAbs	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
site	NULL
consistently	NULL
reduced	NULL
transcription	NULL
by	NULL
75-90	NULL
%	NULL
.	NULL

Most	NULL
studies	NULL
of	NULL
Jurkat	NULL
cells	NULL
have	NULL
used	NULL
PHA	NULL
plus	NULL
PMA	NULL
or	NULL
ionomycin	NULL
plus	NULL
PMA	NULL
to	NULL
activate	NULL
the	NULL
cells	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
studies	NULL
of	NULL
tumor	NULL
cells	NULL
requiring	NULL
the	NULL
use	NULL
of	NULL
nonphysiologic	NULL
activators	NULL
such	NULL
as	NULL
PMA	NULL
may	NULL
additionally	NULL
complicate	NULL
interpretation	NULL
of	NULL
results	NULL
.	NULL

APC	NULL
activate	NULL
T	NULL
cells	NULL
by	NULL
presenting	NULL
antigen	NULL
in	NULL
the	NULL
context	NULL
of	NULL
self-	NULL
MHC	NULL
molecules	NULL
and	NULL
providing	NULL
costimulatory	NULL
signals	NULL
such	NULL
as	NULL
those	NULL
mediated	NULL
by	NULL
CD2	NULL
and	NULL
CD28	NULL
.	NULL

We	NULL
compared	NULL
B	NULL
cells	NULL
,	NULL
bone	NULL
marrow-derived	NULL
``	NULL
professional	NULL
``	NULL
APC	NULL
expressing	NULL
B7	NULL
,	NULL
with	NULL
B7-negative	NULL
EC	NULL
,	NULL
which	NULL
have	NULL
been	NULL
described	NULL
as	NULL
``	NULL
semiprofes-sional	NULL
``	NULL
APC	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
costimulate	NULL
IL-2	NULL
transcription	NULL
and	NULL
secretion	NULL
from	NULL
mitogen-activated	NULL
normal	NULL
T	NULL
cells	NULL
(	NULL
49	NULL
,	NULL
53	NULL
)	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
EC	NULL
can	NULL
stimulate	NULL
allogenic	NULL
T	NULL
cell	NULL
proliferation	NULL
(	NULL
54	NULL
)	NULL
and	NULL
do	NULL
so	NULL
because	NULL
they	NULL
provide	NULL
costimulatory	NULL
signals	NULL
that	NULL
result	NULL
in	NULL
augmented	NULL
IL-2	NULL
transcription	NULL
and	NULL
secretion	NULL
(	NULL
34	NULL
)	NULL
.	NULL

EC	NULL
signal	NULL
T	NULL
cells	NULL
through	NULL
LFA-3-CD2	NULL
and	NULL
CD59-CD2	NULL
interaction	NULL
and	NULL
through	NULL
a	NULL
second	NULL
,	NULL
unidentified	NULL
pathway	NULL
(	NULL
55	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
CD2	NULL
was	NULL
found	NULL
to	NULL
be	NULL
critical	NULL
in	NULL
mediating	NULL
signals	NULL
that	NULL
resulted	NULL
in	NULL
enhanced	NULL
IL-2	NULL
transcription	NULL
and	NULL
secretion	NULL
when	NULL
either	NULL
B	NULL
cells	NULL
or	NULL
EC	NULL
were	NULL
used	NULL
as	NULL
costimulators	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
CD28	NULL
pathway	NULL
proved	NULL
to	NULL
be	NULL
critical	NULL
for	NULL
B	NULL
cell	NULL
costimulation	NULL
of	NULL
transcription	NULL
and	NULL
IL-2	NULL
secretion	NULL
,	NULL
but	NULL
was	NULL
not	NULL
productively	NULL
engaged	NULL
by	NULL
EC	NULL
.	NULL

Thus	NULL
,	NULL
costimulation	NULL
by	NULL
two	NULL
different	NULL
accessory	NULL
cells	NULL
can	NULL
be	NULL
distinguished	NULL
by	NULL
the	NULL
surface	NULL
ligands	NULL
through	NULL
which	NULL
they	NULL
signal	NULL
T	NULL
cells	NULL
.	NULL

It	NULL
is	NULL
likely	NULL
that	NULL
both	NULL
B	NULL
cells	NULL
and	NULL
EC	NULL
also	NULL
signal	NULL
through	NULL
other	NULL
ligands	NULL
,	NULL
not	NULL
addressed	NULL
in	NULL
this	NULL
report	NULL
.	NULL

An	NULL
interesting	NULL
finding	NULL
was	NULL
that	NULL
transcription	NULL
induced	NULL
by	NULL
B	NULL
cells	NULL
or	NULL
EC	NULL
was	NULL
usually	NULL
of	NULL
comparable	NULL
magnitude	NULL
,	NULL
whereas	NULL
secreted	NULL
IL-2	NULL
was	NULL
usually	NULL
greater	NULL
from	NULL
T	NULL
cells	NULL
costimulated	NULL
by	NULL
B	NULL
cells	NULL
.	NULL

One	NULL
explanation	NULL
for	NULL
this	NULL
finding	NULL
is	NULL
that	NULL
B	NULL
cells	NULL
do	NULL
increase	NULL
transcription	NULL
beyond	NULL
that	NULL
registered	NULL
by	NULL
the	NULL
transfected	NULL
promoter	NULL
,	NULL
but	NULL
do	NULL
so	NULL
through	NULL
a	NULL
site	NULL
outside	NULL
of	NULL
the	NULL
600	NULL
base	NULL
pairs	NULL
we	NULL
used	NULL
.	NULL

It	NULL
is	NULL
more	NULL
likely	NULL
that	NULL
B	NULL
cells	NULL
,	NULL
probably	NULL
acting	NULL
through	NULL
CD28	NULL
,	NULL
are	NULL
affecting	NULL
IL-2	NULL
levels	NULL
post-transcriptionally	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
increased	NULL
secretion	NULL
of	NULL
IL-2	NULL
in	NULL
response	NULL
to	NULL
B	NULL
cell	NULL
costimulation	NULL
can	NULL
be	NULL
almost	NULL
completely	NULL
blocked	NULL
by	NULL
CTLA-4-Ig	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
CD28	NULL
signaling	NULL
has	NULL
effects	NULL
on	NULL
IL-2	NULL
stability	NULL
as	NULL
well	NULL
as	NULL
on	NULL
processing	NULL
of	NULL
nuclear	NULL
transcripts	NULL
and	NULL
export	NULL
from	NULL
the	NULL
nucleus	NULL
(	NULL
19	NULL
,	NULL
20	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
mechanism	NULL
has	NULL
also	NULL
been	NULL
described	NULL
for	NULL
regulation	NULL
of	NULL
IL-2	NULL
transcripts	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
CD28	NULL
signaling	NULL
(	NULL
56	NULL
)	NULL
.	NULL

These	NULL
effects	NULL
are	NULL
likely	NULL
specific	NULL
for	NULL
IL-2	NULL
mRNA	NULL
and	NULL
presumably	NULL
would	NULL
not	NULL
affect	NULL
the	NULL
reporter	NULL
gene	NULL
.	NULL

A	NULL
major	NULL
conclusion	NULL
of	NULL
this	NULL
study	NULL
is	NULL
that	NULL
although	NULL
different	NULL
accessory	NULL
cells	NULL
costimulate	NULL
T	NULL
cells	NULL
through	NULL
different	NULL
surface	NULL
ligands	NULL
,	NULL
the	NULL
same	NULL
sites	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
appear	NULL
to	NULL
be	NULL
targeted	NULL
.	NULL

Thus	NULL
,	NULL
for	NULL
both	NULL
B	NULL
cell	NULL
and	NULL
EC	NULL
costimulation	NULL
,	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
and	NULL
pAP-1	NULL
sites	NULL
and	NULL
,	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
,	NULL
the	NULL
NFAT	NULL
,	NULL
NFAP-1	NULL
,	NULL
and	NULL
pOCT	NULL
sites	NULL
are	NULL
critical	NULL
.	NULL

This	NULL
same	NULL
combination	NULL
of	NULL
sites	NULL
was	NULL
also	NULL
important	NULL
for	NULL
signaling	NULL
by	NULL
pairs	NULL
of	NULL
anti-CD2	NULL
mAbs	NULL
.	NULL

A	NULL
surprising	NULL
finding	NULL
in	NULL
these	NULL
studies	NULL
was	NULL
the	NULL
failure	NULL
of	NULL
the	NULL
CD28RE	NULL
mutation	NULL
to	NULL
reduce	NULL
transcription	NULL
induced	NULL
by	NULL
B	NULL
cell	NULL
costimulation	NULL
,	NULL
given	NULL
that	NULL
the	NULL
mutation	NULL
muted	NULL
the	NULL
effects	NULL
of	NULL
anti-CD28	NULL
mAb	NULL
.	NULL

T	NULL
cell	NULL
CD28	NULL
was	NULL
productively	NULL
engaged	NULL
by	NULL
B	NULL
cell	NULL
CD28	NULL
ligands	NULL
in	NULL
these	NULL
experiments	NULL
as	NULL
CTLA-4-Ig	NULL
fusion	NULL
protein	NULL
blocked	NULL
augmentation	NULL
of	NULL
secreted	NULL
IL-2	NULL
.	NULL

The	NULL
most	NULL
likely	NULL
interpretation	NULL
is	NULL
that	NULL
natural	NULL
ligands	NULL
for	NULL
CD28	NULL
may	NULL
deliver	NULL
signals	NULL
that	NULL
differ	NULL
from	NULL
those	NULL
produced	NULL
by	NULL
some	NULL
anti-CD28	NULL
mAbs	NULL
and	NULL
that	NULL
these	NULL
signals	NULL
do	NULL
not	NULL
induce	NULL
activation	NULL
of	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
the	NULL
CD28RE	NULL
.	NULL

Indeed	NULL
,	NULL
a	NULL
recent	NULL
report	NULL
suggests	NULL
that	NULL
not	NULL
all	NULL
signaling	NULL
through	NULL
CD28	NULL
is	NULL
identical	NULL
.	NULL

Using	NULL
a	NULL
panel	NULL
of	NULL
anti-CD28	NULL
mAbs	NULL
,	NULL
NunÃ©s	NULL
et	NULL
al	NULL
.	NULL

(	NULL
57	NULL
)	NULL
found	NULL
that	NULL
whereas	NULL
a	NULL
given	NULL
pair	NULL
of	NULL
anti-CD28	NULL
mAbs	NULL
may	NULL
induce	NULL
similar	NULL
calcium	NULL
fluxes	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
they	NULL
can	NULL
induce	NULL
very	NULL
different	NULL
levels	NULL
of	NULL
IL-2	NULL
secretion	NULL
.	NULL

The	NULL
mAbs	NULL
recognize	NULL
several	NULL
different	NULL
epitopes	NULL
on	NULL
CD28	NULL
,	NULL
and	NULL
the	NULL
implication	NULL
is	NULL
that	NULL
signaling	NULL
through	NULL
CD28	NULL
(	NULL
perhaps	NULL
involving	NULL
different	NULL
epitopes	NULL
)	NULL
activates	NULL
more	NULL
than	NULL
one	NULL
signaling	NULL
pathway	NULL
.	NULL

Alternatively	NULL
,	NULL
B	NULL
cells	NULL
(	NULL
and	NULL
potentially	NULL
EC	NULL
)	NULL
,	NULL
unlike	NULL
single	NULL
mAbs	NULL
,	NULL
provide	NULL
multiple	NULL
costimulatory	NULL
signals	NULL
that	NULL
result	NULL
in	NULL
expression	NULL
of	NULL
functionally	NULL
redundant	NULL
sets	NULL
of	NULL
transcription	NULL
factors	NULL
,	NULL
obviating	NULL
the	NULL
role	NULL
of	NULL
factors	NULL
bound	NULL
to	NULL
the	NULL
CD28RE	NULL
.	NULL

This	NULL
interpretation	NULL
presupposes	NULL
that	NULL
CD28-mediated	NULL
signals	NULL
target	NULL
other	NULL
sites	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
CD28RE	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
CD28RE	NULL
has	NULL
recently	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
members	NULL
of	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
family	NULL
of	NULL
proteins	NULL
,	NULL
specifically	NULL
NFKB1	NULL
(	NULL
p50	NULL
)	NULL
,	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
and	NULL
c-Rel	NULL
(	NULL
38	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
CD28	NULL
may	NULL
also	NULL
activate	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
site	NULL
.	NULL

However	NULL
,	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
,	NULL
the	NULL
NF-KB	NULL
site	NULL
and	NULL
the	NULL
CD28RE	NULL
do	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
a	NULL
functionally	NULL
redundant	NULL
pair	NULL
since	NULL
mutation	NULL
of	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
site	NULL
can	NULL
not	NULL
be	NULL
compensated	NULL
for	NULL
by	NULL
a	NULL
functional	NULL
CD28RE	NULL
.	NULL

Although	NULL
the	NULL
same	NULL
combination	NULL
of	NULL
IL-2	NULL
promoter	NULL
elements	NULL
is	NULL
targeted	NULL
by	NULL
different	NULL
costimulatory	NULL
molecules	NULL
,	NULL
we	NULL
have	NULL
not	NULL
ruled	NULL
out	NULL
the	NULL
possibility	NULL
that	NULL
different	NULL
combinations	NULL
of	NULL
nuclear	NULL
factors	NULL
may	NULL
bind	NULL
to	NULL
these	NULL
sites	NULL
.	NULL

Indeed	NULL
,	NULL
we	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
when	NULL
T	NULL
cells	NULL
are	NULL
costimulated	NULL
by	NULL
EC	NULL
,	NULL
they	NULL
express	NULL
enhanced	NULL
levels	NULL
of	NULL
c-Fos	NULL
mRNA	NULL
,	NULL
and	NULL
the	NULL
AP-1	NULL
complex	NULL
that	NULL
binds	NULL
to	NULL
the	NULL
pAP-1	NULL
site	NULL
contains	NULL
severalfold	NULL
higher	NULL
levels	NULL
of	NULL
Fos	NULL
protein	NULL
compared	NULL
with	NULL
cells	NULL
activated	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EC	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
a	NULL
c-Fos	NULL
knockout	NULL
mouse	NULL
has	NULL
recently	NULL
been	NULL
generated	NULL
that	NULL
displays	NULL
normal	NULL
IL-2	NULL
induction	NULL
,	NULL
suggesting	NULL
that	NULL
other	NULL
Fos	NULL
proteins	NULL
can	NULL
substitute	NULL
for	NULL
c-Fos	NULL
in	NULL
these	NULL
mice	NULL
(	NULL
58	NULL
)	NULL
.	NULL

There	NULL
are	NULL
also	NULL
multiple	NULL
NFAT	NULL
proteins	NULL
that	NULL
may	NULL
have	NULL
differing	NULL
roles	NULL
under	NULL
different	NULL
conditions	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
in	NULL
response	NULL
to	NULL
different	NULL
accessory	NULL
cells	NULL
,	NULL
sequential	NULL
expression	NULL
of	NULL
nuclear	NULL
factors	NULL
,	NULL
expression	NULL
of	NULL
different	NULL
family	NULL
members	NULL
,	NULL
or	NULL
expression	NULL
of	NULL
factors	NULL
with	NULL
longer	NULL
half-lives	NULL
,	NULL
for	NULL
example	NULL
,	NULL
may	NULL
affect	NULL
transcription	NULL
.	NULL

Indeed	NULL
,	NULL
IL-2	NULL
mRNA	NULL
levels	NULL
remain	NULL
elevated	NULL
longer	NULL
in	NULL
the	NULL
presence	NULL
than	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EC	NULL
costimula-	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10Â°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
IL-2	NULL
Transcription	NULL
in	NULL
Peripheral	NULL
Blood	NULL
Lymphocytes	NULL
tion	NULL
.	NULL
``	NULL

The	NULL
data	NULL
presented	NULL
in	NULL
this	NULL
study	NULL
define	NULL
the	NULL
sites	NULL
most	NULL
relevant	NULL
for	NULL
future	NULL
study	NULL
of	NULL
nuclear	NULL
factor	NULL
binding	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
our	NULL
findings	NULL
suggest	NULL
that	NULL
the	NULL
IL-2	NULL
promoter	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
integrates	NULL
signals	NULL
by	NULL
using	NULL
a	NULL
combination	NULL
of	NULL
several	NULL
sites	NULL
to	NULL
activate	NULL
transcription	NULL
.	NULL

This	NULL
model	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
a	NULL
previous	NULL
proposal	NULL
describing	NULL
fine	NULL
tuning	NULL
of	NULL
IL-2	NULL
transcription	NULL
(	NULL
83	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
these	NULL
studies	NULL
emphasize	NULL
the	NULL
feasibility	NULL
of	NULL
working	NULL
with	NULL
normal	NULL
nontransformed	NULL
cells	NULL
and	NULL
the	NULL
possibility	NULL
that	NULL
such	NULL
cells	NULL
may	NULL
differ	NULL
in	NULL
significant	NULL
ways	NULL
from	NULL
the	NULL
tumor	NULL
cells	NULL
that	NULL
have	NULL
become	NULL
``	NULL
standard	NULL
``	NULL
models	NULL
for	NULL
the	NULL
study	NULL
of	NULL
transcriptional	NULL
regulation	NULL
.	NULL

Acknowledgments-We	NULL
thank	NULL
Louise	NULL
Benson	NULL
and	NULL
Gwen	NULL
Davis	NULL
for	NULL
help	NULL
with	NULL
cell	NULL
culture	NULL
,	NULL
Tom	NULL
Taylor	NULL
for	NULL
help	NULL
with	NULL
FACS	NULL
,	NULL
Chris	NULL
Benjamin	NULL
for	NULL
CD2	NULL
antibodies	NULL
,	NULL
Tim	NULL
Springer	NULL
for	NULL
antibodies	NULL
,	NULL
and	NULL
Gary	NULL
Gray	NULL
for	NULL
CD28	NULL
antibodies	NULL
and	NULL
fusion	NULL
proteins	NULL
.	NULL

REFERENCES	NULL
.	NULL

Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1985	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

8	NULL
,	NULL
237-261	NULL
.	NULL

Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
248	NULL
,	NULL
355-361	NULL
.	NULL

Smith	NULL
,	NULL
K.	NULL
A	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Science	NULL
240	NULL
,	NULL
1169-1176	NULL
.	NULL

Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1990	NULL
)	NULL
Science	NULL
248	NULL
,	NULL
1349-1356	NULL
.	NULL

Hughes	NULL
,	NULL
C.	NULL
C.	NULL
W.	NULL
,	NULL
Savage	NULL
,	NULL
C.	NULL
O.	NULL
S.	NULL
,	NULL
and	NULL
Pober	NULL
,	NULL
J.	NULL
S.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

171	NULL
,	NULL
1453-1467	NULL
.	NULL

Damle	NULL
,	NULL
N.	NULL
K.	NULL
,	NULL
Klussman	NULL
,	NULL
K.	NULL
,	NULL
Linsley	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
and	NULL
Aruffo	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

148	NULL
,	NULL
1985-1992	NULL
7	NULL
.	NULL

Bierer	NULL
,	NULL
B.	NULL
E.	NULL
,	NULL
Barbosa	NULL
,	NULL
J.	NULL
,	NULL
Herrmann	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Burakoff	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

140	NULL
,	NULL
3358-3363	NULL
8	NULL
.	NULL

Menu	NULL
,	NULL
E.	NULL
,	NULL
Tsai	NULL
,	NULL
B.	NULL
C.	NULL
,	NULL
Bothwell	NULL
,	NULL
A.	NULL
L.	NULL
M.	NULL
,	NULL
Sims	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
and	NULL
Bierer	NULL
,	NULL
B.	NULL
E.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

158	NULL
,	NULL
2444-2456	NULL
9	NULL
.	NULL

Young	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Koulova	NULL
,	NULL
L.	NULL
,	NULL
Scergel	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Clark	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Steinman	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
and	NULL
Dupont	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

90	NULL
,	NULL
229-237	NULL
10	NULL
.	NULL

Boussiotis	NULL
,	NULL
V.	NULL
A.	NULL
,	NULL
Freeman	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Gribben	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Daley	NULL
,	NULL
J.	NULL
,	NULL
Gray	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Nadler	NULL
,	NULL
L.	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

90	NULL
,	NULL
11059-11063	NULL
11	NULL
.	NULL

Hathcock	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Laszlo	NULL
,	NULL
G.	NULL
,	NULL
Dickler	NULL
,	NULL
H.	NULL
B.	NULL
,	NULL
Bradshaw	NULL
,	NULL
J.	NULL
,	NULL
Linsley	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Hodes	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Science	NULL
262	NULL
,	NULL
905-907	NULL
12	NULL
.	NULL

Lenschow	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Su	NULL
,	NULL
G.	NULL
,	NULL
Zuckerman	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Nabavi	NULL
,	NULL
N.	NULL
,	NULL
Jellis	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
Gray	NULL
,	NULL
G.	NULL
S.	NULL
,	NULL
Miller	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Bluestone	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

90	NULL
,	NULL
11054-11058	NULL
13	NULL
.	NULL

Freeman	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Gribben	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Boussiotis	NULL
,	NULL
V.	NULL
A.	NULL
,	NULL
Ng	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Restivo	NULL
,	NULL
V.	NULL
J.	NULL
,	NULL
Lombard	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Gray	NULL
,	NULL
G.	NULL
S.	NULL
,	NULL
and	NULL
Nadler	NULL
,	NULL
L.	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Science	NULL
262	NULL
,	NULL
909-911	NULL
14	NULL
.	NULL

Damle	NULL
,	NULL
N.	NULL
K.	NULL
,	NULL
Klussman	NULL
,	NULL
K.	NULL
,	NULL
Leytze	NULL
,	NULL
G.	NULL
,	NULL
Myrdal	NULL
,	NULL
S.	NULL
,	NULL
Aruffo	NULL
,	NULL
A.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Linsley	NULL
,	NULL
P.	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

152	NULL
,	NULL
2686-2697	NULL
15	NULL
.	NULL

Walunas	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
Lenschow	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Bakker	NULL
,	NULL
C.	NULL
Y.	NULL
,	NULL
Linsley	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
Freeman	NULL
,	NULL
G.	NULL
F.	NULL
,	NULL
Green	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Thompson	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
and	NULL
Bluestone	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Immunity	NULL
1	NULL
,	NULL
405-413	NULL
16	NULL
.	NULL

Jenkins	NULL
,	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Immunity	NULL
1	NULL
,	NULL
448-446	NULL
17	NULL
.	NULL

Johnson	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Jenkins	NULL
,	NULL
M.	NULL
K.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

152	NULL
,	NULL
429-437	NULL
18	NULL
.	NULL

D'Ambrosio	NULL
,	NULL
D.	NULL
,	NULL
Trotta	NULL
,	NULL
R.	NULL
,	NULL
Vacca	NULL
,	NULL
A.	NULL
,	NULL
Frati	NULL
,	NULL
L.	NULL
,	NULL
Santoni	NULL
,	NULL
A.	NULL
,	NULL
Gulino	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Testi	NULL
,	NULL
R.	NULL
(	NULL
19983	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

28	NULL
,	NULL
2993-2997	NULL
19	NULL
.	NULL

Umlauf	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
Beverly	NULL
,	NULL
B.	NULL
,	NULL
Lantz	NULL
,	NULL
O.	NULL
,	NULL
and	NULL
Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
3197-3205	NULL
20	NULL
.	NULL

Lindsten	NULL
,	NULL
T.	NULL
,	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Stella	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Science	NULL
244	NULL
,	NULL
389-343	NULL
21	NULL
.	NULL

Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Shaw	NULL
,	NULL
J.-P.	NULL
,	NULL
Bush	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Replogle	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Belagaje	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8	NULL
,	NULL
1715-1724	NULL
22	NULL
.	NULL

Novak	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
White	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
and	NULL
Rothenberg	NULL
,	NULL
E.	NULL
V.	NULL
(	NULL
1990	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

18	NULL
,	NULL
4523-4533	NULL
23	NULL
.	NULL

McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Luo	NULL
,	NULL
C.	NULL
,	NULL
Kerppola	NULL
,	NULL
T.	NULL
K.	NULL
,	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
Badalian	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Ho	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Burgeon	NULL
,	NULL
E.	NULL
,	NULL
Lane	NULL
,	NULL
W.	NULL
S.	NULL
,	NULL
Lambert	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Curran	NULL
,	NULL
T.	NULL
,	NULL
Verdine	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Rao	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Hogan	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1993	NULL
)	NULL
Science	NULL
262	NULL
,	NULL
750-754	NULL
grim	NULL
co	NULL
bo	NULL
|-	NULL
fed	NULL
2	NULL
C.	NULL
C.	NULL
W.	NULL
Hughes	NULL
and	NULL
J.	NULL
S.	NULL
Pober	NULL
,	NULL
unpublished	NULL
observations	NULL
.	NULL

24	NULL
25	NULL
26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

5377	NULL
.	NULL

Serfling	NULL
,	NULL
E.	NULL
,	NULL
Barthelmas	NULL
,	NULL
R.	NULL
,	NULL
Pfeuffer	NULL
,	NULL
I.	NULL
,	NULL
Schenk	NULL
,	NULL
B.	NULL
,	NULL
Zarius	NULL
,	NULL
S.	NULL
,	NULL
Swoboda	NULL
,	NULL
R.	NULL
,	NULL
Mercurio	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

8	NULL
,	NULL
465-473	NULL
.	NULL

Boise	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
Petryniak	NULL
,	NULL
B.	NULL
,	NULL
Mao	NULL
,	NULL
X.	NULL
,	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Wang	NULL
,	NULL
C.	NULL
Y.	NULL
,	NULL
Lindsten	NULL
,	NULL
T.	NULL
,	NULL
Bravo	NULL
,	NULL
R.	NULL
,	NULL
Kovary	NULL
,	NULL
K.	NULL
,	NULL
Leiden	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13	NULL
,	NULL
1911-1919	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
Valge-Archer	NULL
,	NULL
V.	NULL
E.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

148	NULL
,	NULL
1240-1250	NULL
Emmel	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Verweij	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Higgins	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Lacy	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
246	NULL
,	NULL
1617-1620	NULL
Hoyos	NULL
,	NULL
B.	NULL
,	NULL
Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Bihnlein	NULL
,	NULL
E.	NULL
,	NULL
Siekevitz	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
244	NULL
,	NULL
457-460	NULL
Williams	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Moolten	NULL
,	NULL
D.	NULL
,	NULL
Burlein	NULL
,	NULL
J.	NULL
,	NULL
Romano	NULL
,	NULL
J.	NULL
,	NULL
Bhaerman	NULL
,	NULL
R.	NULL
,	NULL
Godillot	NULL
,	NULL
A.	NULL
,	NULL
Mellon	NULL
,	NULL
M.	NULL
,	NULL
Rauscher	NULL
,	NULL
F.	NULL
J.	NULL
,	NULL
and	NULL
Kant	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Science	NULL
254	NULL
,	NULL
1791-1794	NULL
Fraser	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
and	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
4357-4363	NULL
Kamps	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Corcoran	NULL
,	NULL
L.	NULL
,	NULL
LeBowitz	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10	NULL
,	NULL
5464-5472	NULL
Skerka	NULL
,	NULL
C.	NULL
,	NULL
Decker	NULL
,	NULL
E.	NULL
L.	NULL
,	NULL
and	NULL
Zipfel	NULL
,	NULL
P.	NULL
F.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
22500-22506	NULL
Hentsch	NULL
,	NULL
B.	NULL
,	NULL
Mouzaki	NULL
,	NULL
A.	NULL
,	NULL
Pfeuffer	NULL
,	NULL
I.	NULL
,	NULL
Rungger	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Serfling	NULL
,	NULL
E.	NULL
(	NULL
1992	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

20	NULL
,	NULL
2657-2665	NULL
Hughes	NULL
,	NULL
C.	NULL
C.	NULL
W.	NULL
,	NULL
and	NULL
Pober	NULL
,	NULL
J.	NULL
S.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

150	NULL
,	NULL
3148-3160	NULL
Muegge	NULL
,	NULL
K.	NULL
,	NULL
Williams	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Kant	NULL
,	NULL
J.	NULL
,	NULL
Karin	NULL
,	NULL
M.	NULL
,	NULL
Chiu	NULL
,	NULL
R.	NULL
,	NULL
Schmidt	NULL
,	NULL
A.	NULL
,	NULL
Siebenlist	NULL
,	NULL
U.	NULL
,	NULL
Young	NULL
,	NULL
H.	NULL
A.	NULL
,	NULL
and	NULL
Durum	NULL
,	NULL
S.	NULL
K.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
246	NULL
,	NULL
249-251	NULL
Novak	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
Chen	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Rothenberg	NULL
,	NULL
E.	NULL
V.	NULL
(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10	NULL
,	NULL
6325-6334	NULL
Lai	NULL
,	NULL
J.-H.	NULL
,	NULL
Horvath	NULL
,	NULL
G.	NULL
,	NULL
Subleski	NULL
,	NULL
J.	NULL
,	NULL
Bruder	NULL
,	NULL
J.	NULL
,	NULL
Ghosh	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Tan	NULL
,	NULL
T.-H.	NULL
(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
4260-4271	NULL
Ghosh	NULL
,	NULL
P.	NULL
,	NULL
Tan	NULL
,	NULL
T.	NULL
H.	NULL
,	NULL
Rice	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
Sica	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Young	NULL
,	NULL
H.	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

90	NULL
,	NULL
1696-1700	NULL
Fraser	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Irving	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Science	NULL
251	NULL
,	NULL
313-316	NULL
Civil	NULL
,	NULL
A.	NULL
,	NULL
Geerts	NULL
,	NULL
M.	NULL
,	NULL
Aarden	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
and	NULL
Verweij	NULL
,	NULL
C.	NULL
L.	NULL
(	NULL
1992	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

22	NULL
,	NULL
3041-3048	NULL
Kang	NULL
,	NULL
S.	NULL
,	NULL
Tran	NULL
,	NULL
A.	NULL
,	NULL
Grilli	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Lenardo	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Science	NULL
256	NULL
,	NULL
1452-1456	NULL
Chrivia	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Wedrychowicz	NULL
,	NULL
T.	NULL
,	NULL
Young	NULL
,	NULL
H.	NULL
A.	NULL
,	NULL
and	NULL
Hardy	NULL
,	NULL
K.	NULL
J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172	NULL
,	NULL
661-664	NULL
Gimbrone	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Jr.	NULL
(	NULL
1976	NULL
)	NULL
Prog	NULL
.	NULL

Hemostasis	NULL
Thromb	NULL
.	NULL

8	NULL
,	NULL
1-28	NULL
Thornton	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Mueller	NULL
,	NULL
S.	NULL
N.	NULL
,	NULL
and	NULL
Levine	NULL
,	NULL
E.	NULL
M.	NULL
(	NULL
1983	NULL
)	NULL
Science	NULL
222	NULL
,	NULL
623-625	NULL
Higuchi	NULL
,	NULL
R.	NULL
(	NULL
1990	NULL
)	NULL
in	NULL
PCR	NULL
Protocols	NULL
:	NULL
A	NULL
Guide	NULL
to	NULL
Methods	NULL
and	NULL
Applications	NULL
(	NULL
Innis	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Gelfand	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
Sninsky	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
and	NULL
White	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
eds	NULL
)	NULL
pp	NULL
.	NULL

177-183	NULL
,	NULL
Academic	NULL
Press	NULL
,	NULL
Inc.	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
Sambrook	NULL
,	NULL
J.	NULL
,	NULL
Fritsch	NULL
,	NULL
E.	NULL
F.	NULL
,	NULL
and	NULL
Maniatis	NULL
,	NULL
T.	NULL
(	NULL
1989	NULL
)	NULL
Molecular	NULL
Cloning	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
Fischer	NULL
,	NULL
G.	NULL
F.	NULL
,	NULL
Holter	NULL
,	NULL
W.	NULL
,	NULL
Maijdic	NULL
,	NULL
O.	NULL
,	NULL
Cragoe	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
and	NULL
Knapp	NULL
,	NULL
W.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

141	NULL
,	NULL
404-409	NULL
Kumagai	NULL
,	NULL
N.	NULL
,	NULL
Benedict	NULL
,	NULL
S.	NULL
H.	NULL
,	NULL
Mills	NULL
,	NULL
G.	NULL
B.	NULL
,	NULL
and	NULL
Gelfand	NULL
,	NULL
E.	NULL
W.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

189	NULL
,	NULL
1393-1399	NULL
Karmann	NULL
,	NULL
K.	NULL
,	NULL
Pober	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
and	NULL
Hughes	NULL
,	NULL
C.	NULL
C.	NULL
W.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

158	NULL
,	NULL
3929-3937	NULL
Shaw	NULL
,	NULL
J.-P.	NULL
,	NULL
Utz	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Toole	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Emmel	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Science	NULL
241	NULL
,	NULL
202-205	NULL
Brombacher	NULL
,	NULL
F.	NULL
,	NULL
Schiifer	NULL
,	NULL
T.	NULL
,	NULL
Weissenstein	NULL
,	NULL
U.	NULL
,	NULL
Tschopp	NULL
,	NULL
C.	NULL
,	NULL
Andersen	NULL
,	NULL
E.	NULL
,	NULL
Biirki	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Baumann	NULL
,	NULL
G.	NULL
(	NULL
1994	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

6	NULL
,	NULL
189-197	NULL
Sha	NULL
,	NULL
W.	NULL
C.	NULL
,	NULL
Liou	NULL
,	NULL
H.-C.	NULL
,	NULL
Tuomanen	NULL
,	NULL
E.	NULL
I.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1995	NULL
)	NULL
Cell	NULL
80	NULL
,	NULL
321-330	NULL
Murray	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
Khodadoust	NULL
,	NULL
M.	NULL
K.	NULL
,	NULL
Pober	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
and	NULL
Bothwell	NULL
,	NULL
A.	NULL
L.	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Immunity	NULL
1	NULL
,	NULL
57-63	NULL
Savage	NULL
,	NULL
C.	NULL
O.	NULL
S.	NULL
,	NULL
Hughes	NULL
,	NULL
C.	NULL
C.	NULL
W.	NULL
,	NULL
McIntyre	NULL
,	NULL
B.	NULL
W.	NULL
,	NULL
Picard	NULL
,	NULL
J.	NULL
K.	NULL
,	NULL
and	NULL
Pober	NULL
,	NULL
J	NULL
.	NULL

8	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Transplantation	NULL
(	NULL
Baltimore	NULL
)	NULL
56	NULL
,	NULL
128-134	NULL
Savage	NULL
,	NULL
C.	NULL
0	NULL
.	NULL

S.	NULL
,	NULL
Hughes	NULL
,	NULL
C.	NULL
C.	NULL
W.	NULL
,	NULL
Pepinsky	NULL
,	NULL
R.	NULL
B.	NULL
,	NULL
Wallner	NULL
,	NULL
B.	NULL
P.	NULL
,	NULL
Freedman	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
and	NULL
Pober	NULL
,	NULL
J.	NULL
S.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
.	NULL

Immunol	NULL
.	NULL

187	NULL
,	NULL
150-163	NULL
Gerez	NULL
,	NULL
L.	NULL
,	NULL
Arad	NULL
,	NULL
G.	NULL
,	NULL
Efrat	NULL
,	NULL
S.	NULL
,	NULL
Ketzinel	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Kaempfer	NULL
,	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
19569-19575	NULL
NunÃ©s	NULL
,	NULL
J.	NULL
,	NULL
Klasen	NULL
,	NULL
S.	NULL
,	NULL
Ragueneau	NULL
,	NULL
M.	NULL
,	NULL
Pavon	NULL
,	NULL
C.	NULL
,	NULL
Couez	NULL
,	NULL
D.	NULL
,	NULL
Mawas	NULL
,	NULL
C.	NULL
,	NULL
Bagnasco	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Olive	NULL
,	NULL
D.	NULL
(	NULL
1993	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

5	NULL
,	NULL
811-815	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
Nalefski	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Johnson	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
Spiegelman	NULL
,	NULL
B.	NULL
M.	NULL
,	NULL
Papaioannou	NULL
,	NULL
V.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
1566-1574	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10Â°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Transcriptional	NULL
Regulation	NULL
of	NULL
the	NULL
Interleukin-2	NULL
Gene	NULL
in	NULL
Normal	NULL
Human	NULL
Peripheral	NULL
Blood	NULL
T	NULL
Cells	NULL
:	NULL
CONVERGENCE	NULL
OF	NULL
COSTIMULATORY	NULL
SIGNALS	NULL
AND	NULL
DIFFERENCES	NULL
FROM	NULL
TRANSFORMED	NULL
T	NULL
CELLS	NULL
Christopher	NULL
C.	NULL
W.	NULL
Hughes	NULL
and	NULL
Jordan	NULL
S.	NULL
Pober	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1996	NULL
,	NULL
271:5369-5377.	NULL
doi	NULL
:	NULL
10.1074/jb0.271.10.5369	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/271/10/5369	NULL
Alerts	NULL
:	NULL
Â«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
Â«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
56	NULL
references	NULL
,	NULL
40	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
0/5369	NULL
full.html	NULL
#	NULL
ref-list-1	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
4q	NULL
/S10Â°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL

